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The ubiquitin system regulates several diverse biological processes in eukaryotes. The 
process of ubiquitination involves a multienzymatic E1-E2-E3 cascade that serves to activate 
ubiquitin, conjugate the C-terminus of ubiquitin, and finaly to ligate the ubiquitin molecule to a 
substrate protein via the E3 ligase. Deubiquitinating enzymes (DUBs) reverse these ubiquitin 
modifications. OTUB1 is a highly expressed DUB that specificaly cleaves K48 poly-ubiquitin 
chains. It helps to regulate ubiquitin concentrations in the cel through its catalytic and non-
canonical activities. OTUB1 possesses a unique property among DUBs in that it binds to a 
subset of ubiquitin conjugating enzymes, E2s, independently of its catalytic activity. By 
interacting with E2s, a cross-regulation occurs in which the E2s stimulate OTUB1’s isopeptidase 
activity and, in turn, OTUB1 inhibits the E2’s ability to transfer ubiquitin. Mass 
spectrometry/proteomics studies revealed that OTUB1 interacts with 7 E2s in cels: UBE2D1, 
UBE2D2, UBE2D3, UBE2N, UBE2E1, UBE2E2, and UBE2E3. It is unclear whether cross-
regulation occurs in vivo. To investigate the mechanism involved in the OTUB1:E2 cross-
regulatory complex, I utilized a series of biochemical and kinetic assays. First, I looked at 
stimulation by determining EC50s and Michaelis Menten kinetic parameters using a FRET assay 
and quantified the degree of stimulated isopeptidase activity with each E2. I found that binding 
of an E2 lowers the KM of OTUB1 for K48 diUb, at a broad range of stimulation depending on 
the E2, with litle to no change in the kcat. This result indicates that the E2 increases OTUB1’s 
afinity for K48 diUb. I used ITC to confirm this, my results indicate that the interactions between 
OTUB1 and the E2 produces an increase in OTUB1’s afinity for K48 chains. I next sought to 
characterize OTUB1’s inhibitory efects on E2 ubiquitin conjugation. Similar to previous studies, 
OTUB1 blocks both UBE2N and UBE2D proteins from free chain poly-ubiquitination. Unlike 
UBE2D or UBE2N where OTUB1 inhibits their poly-ubiquitination activity, OTUB1 predominantly 
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serves to stop autoubiquitylation of UBE2E enzymes. Further in vivo studies revealed that 
autoubiquitylation of UBE2E1 targets it from proteasomal degradation. By inhibiting 
autoubiquitylation, OTUB1 stabilizes UBE2E1; a novel role for OTUB1. 
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Chapter 1: Ubiquitin conjugating and deconjugating enzymes working 
in concert together 
 
1.1 Ubiquitination, a multienzymatic process 
 
Ubiquitin is a smal 76 amino acid protein that is covalently atached to substrate and plays a 
role in diverse celular pathways within the eukaryotic cel. Historicaly, the first function 
identified for ubiquitin was its role in the proteasomal degradation of a protein substrate. Since 
then, the field has uncovered ever expanding roles for this smal modifier. Not only does 
ubiquitin participate in other proteolytic pathways such as endolysosomal degradation and 
autophagy (Clague and Urbé, 2010; Kirkin et al., 2009), but it is also essential for non-
degradative processes such as intracelular traficking, DNA damage repair mechanisms, cel 
cycle and division, and other regulatory pathways (Chen and Sun, 2009; Schnel and Hicke, 
2003; Swatek and Komander, 2016).  
 
The ubiquitin C-terminus is conjugated to lysine residues via a multienzymatic process, the E1-
E2-E3 cascade (Figure 1.1.a). First, an E1 ubiquitin activating enzyme activates the C-terminal 
carboxylate of ubiquitin with ATP to form a highly reactive Ub-AMP adenylate (Pickart, 2001). 
The active site cysteine on the E1 then atacks the activated ubiquitin to form a thioester linkage 
with the C-terminus of ubiquitin, E1~Ub. Next, E1~Ub binds to a ubiquitin conjugating enzyme, 
E2, and transfers the ubiquitin from the E1 to the E2 catalytic cysteine, producing a thioester 
linked ubiquitin molecule to the E2, E2~Ub (Figure 1.2.c) (Ye and Rape, 2009). Finaly, an E3 
ligase mediates the transfer of ubiquitin from the charged E2 to a substrate by simultaneously 
interacting with both the E2 and substrate (Zheng and Shabeck, 2017), resulting in formation of 
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an isopeptide linkage between the ubiquitin C-terminus and the lysine ε-amino in a target 
substrate.  
 
Ubiquitin itself has lysine residues and can be a substrate of the E1-E2-E3 cascade, resulting in 
formation of polyubiquitin chains (Komander and Rape, 2012). Ubiquitin contains seven lysines 
(K6, K11, K22, K29, K33, K48, K63) and an N-terminal amino group (M1) that can be covalently 
modified with another ubiquitin molecule. Ubiquitin chains are denoted by the isopeptide linkage 
that connects the acceptor ubiquitin lysine ε-amino to the C-terminus of the donor ubiquitin 
(Figure 1.2). E2 enzymes are generaly responsible for specifying the type of ubiquitin linkage 
(David et al., 2010). Diferent chain types signal for very diferent biological outcomes (Table 
1.1). Of the various chain types, K48- and K63-linked polyubiquitin chains are the most 
abundant types of chains found in cels (Clague et al., 2015). K48 chains target proteins for 
proteasomal degradation, whereas K63 chains signal for double stranded DNA damage repair 
mechanisms in addition to signaling for autophagy (Komander and Rape, 2012; Li and Ye, 
2008). K11 chains play a role in cel cycle control (Matsumoto et al., 2010). The metazoan 
anaphase-promoting complex (APC/C) makes K11 chains that signal for proteasomal 
degradation and mitotic exit. In addition, K29 chains inhibit Wnt signaling (Fei et al., 2013), K33 
chains serve as negative regulators for both AMP-activated protein kinases (Al-Hakim et al., 
2008) and T-cel antigen receptors (Huang et al., 2010), and linear linkages or M1 chains are 
key regulators of NF-KB signaling (Gerlach et al., 2011; Iwai and Tokunaga, 2009). The 
diversity of biological outcomes regulated by these various chain types emphasizes the 
importance of the ubiquitin system in cels. 
 
Total ubiquitin levels in human cels are estimated to be between 17-85 μM depending on cel 
type (Clague et al., 2015). Celular ubiquitin exists in diferent forms: ‘free ubiquitin’, ‘activated or 
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charged’ to an enzyme, ‘conjugated’ to a target substrate, or formed in ‘chains’ (Figure 1.2.c). 
Over 60% of ubiquitin in humans cels is found in the form of monoubiquitylation, with a large 
subset of that percentage pertaining to ubiquitin that is conjugated to histones (Clague et al., 
2015). Monoubiquitinated H2A (Zhou et al., 2008) and H2B (Chandrasekharan et al., 2009) play 
a critical role in transcription regulation. 11% of the total ubiquitin in the cel is found conjugated 
in chains, particularly in either K48- or K63- linkages (Clague et al., 2015). 
 
1.2 E2 Ubiquitin Conjugating Enzymes specify linkage type 
 
In mammals, there are ~40 E2s that conjugate ubiquitin or ubiquitin-like modifiers (Stewart et 
al., 2016 ; Ye and Rape, 2009). Al E2s contain a highly conserved 150-amino acid ubiquitin 
conjugating (Ubc) domain that adopts an α/β fold composed of four α-helices and four β-sheets 
connected by several loops (Figure 1.3.a) (Stewart et al., 2016 ). The Ubc domain contains a 
catalytic cysteine that forms a thioester with the ubiquitin C-terminus. The N-terminal helix α1 
and several loop regions serve as key surfaces that interact with both E1 and E3 enzymes (Eletr 
et al., 2005; Ye and Rape, 2009). Since the E2 cannot be simultaneously bound to both 
proteins, the E1 must dissociate from the E2 after generating the E2~Ub thioester intermediate 
in order to alow an E3 ligase to bind and mediate transfer of the ubiquitin from the E2 to the 
substrate (Eletr et al., 2005; Stewart et al., 2016 ). In the absence of an E3 ligase, E2 activity is 
low and is typicaly non-specific (Ozkan et al., 2005; Petroski and Deshaies, 2005). 
 
E2 enzymes are subdivided into four classes based on domain architecture (Figure 1.3.b) 
(Stewart et al., 2016 ). Diferences in classes are based on extensions to the Ubc domain (Class 
I) at either the N- (Class II) or C-terminus (Class I). Additionaly, Class IV E2s contain both N- 
and C-terminal extensions. These extensions are often intrinsicaly disordered and can impart 
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additional functionality to the E2 (Schumacher et al., 2013). The UBE2E family of enzymes 
comprises Class II E2s whose N-terminal extension limits polyubiquitinating activity 
(Schumacher et al., 2013). The C-terminal extension of UBE2K, a Class I E2, interacts with 
ubiquitin and is necessary for assembling K48-linked chains in a processive manner (Haldeman 
et al., 1997). Of the 40 diferent E2 enzymes, a subset are E2 variants (UEV) that possess a 
Ubc domain that lacks a catalytic cysteine and is therefore unable to conjugate ubiquitin 
(Hofmann and Pickart, 1999b; Sancho et al., 1998; VanDemark et al., 2001). As described 
below, these UEV proteins have a specialized function in assisting UBE2N to synthesize K63 
chains (Eddins et al., 2006; Hofmann and Pickart, 1999a). 
 
E2 linkage specificity likely occurs from the E2, charged with a donor ubiquitin, positioning the 
acceptor ubiquitin in such a way that exposes the acceptor lysine for atack. This is best 
understood in the case of K63-linked chains, which are synthesized by UBE2N in humans and 
Ubc13 in yeast (Eddins et al., 2006; Hofmann and Pickart, 1999b; Yin et al., 2009). Biochemical 
and structural studies have elucidated the mechanism by which Ubc13/Mms2 forms K63 chains 
(Eddins et al., 2006; Hofmann and Pickart, 1999a). When Ubc13 is charged with the donor 
ubiquitin, the acceptor ubiquitin is non-covalently bound to Mms2 (Eddins et al., 2006) in an 
orientation that places K63 of the acceptor ubiquitin in a position to atack the thioester linkage 
of Ubc13~Ub. This process can occur iteratively, leading to elongation of K63-linked 
polyubiquitin chains. The human homologues, UBE2N/UEV1A, function in an identical manner 
(Yin et al., 2009). 
 
Despite sharing a high degree of sequence and structural similarity, there is high variability in 
the types of chains that an E2 can form (David et al., 2010). Some E2s primarily initiate the 
conjugation of a polyubiquitin chain by monoubiquitinating the substrate, while others elongate 
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the chain (David et al., 2010). Some E2 enzymes are promiscuous and can generate several 
diferent polyubiquitin linkages. The UBE2D family of E2s function with a wide variety of E3 
ligases to form diferent K48-, K29-, and K11-linked chains, as wel as monoubiquitinated 
substrates (Brzovic and Klevit, 2006; Brzovic et al., 2006; David et al., 2010; Sakata et al., 
2010). The UBE2E family of E2s (Banka et al., 2015; Schumacher et al., 2013), UBE2E2 and 
UBE2E3, have been found predominantly through mass spectrometry studies to form mixtures 
of K48, K63, and K11 chains (David et al., 2010). Certain E2 enzymes can be quite specific for 
the type of the linkage type they form. As mentioned above, UBE2N/UEV1a makes only K63-
linked polyubiquitin chains. However, UBE2N/UEV1a only elongates ubiquitin chains and 
cannot initiate formation of a K63-linked chain on a non-ubiquitin substrate. UBE2N/UEV1a 
therefore cannot to monoubiquitylate a substrate unless that substrate is free ubiquitin (Petroski 
and al., 2007; Windheim et al., 2008). UBE2S selectively forms K11 chains on the E3, 
anaphase-promoting complex (APC/C), and, similar to UBE2N/UEV1a, only functions as a chain 
elongator (Jin et al., 2008; Wiliamson and al., 2009). UBE2K is a Class I E2 whose C-terminal 
extension is needed to selectively form K48-linked chains on monoubiquitinated substrates with 
RING E3s (Buetow and al., 2015; Chen and Pickart, 1990; Middleton and Day, 2015; 
Plechanovov et al., 2012). In the absence of an E3, UBE2K forms primarily diUbiquitinfrom free 
ubiquitin (Chen and Pickart, 1990; Middleton and Day, 2015). These chain-elongating E2s rely 
on monoubiquitinating E2s (UBE2D, UBE2W, UBE2C) to initiate formation of a chain on a 
substrate protein. Since UBE2D enzymes lack lysine specificity, they can promiscuously 
conjugate monoubiquitin to substrates in concert with a diverse aray of E3 ligases (Brzovic and 
Klevit, 2006). UBE2W is unique in that it primarily monoubiquitinates substrates by conjugating 
ubiquitin to the N-terminus of substrate proteins (Fletcher et al., 2015; Scaglione et al., 2013; 
Tatham et al., 2013). UBE2C monoubiquitinates the E3 ligase, APC/C, alowing UBE2S to 
further polyubiquitinate with K11 chains which then signals for substrate proteasomal 
 6 
degradation during mitosis (Matsumoto et al., 2010; Rape et al., 2006). In addition to the 
UBE2D family of enzymes, there are several E2s that catalyze chain initiation and elongation for 
specific chain types. UBE2R1 (also known as Cdc34) is an E2 that cooperates with the E3, 
SCF, to eficiently form K48-linked chains on a cel cycle inhibitor which triggers the degradation 
of the inhibitor and signals the cels for entry into S phase (Petroski and Deshaies, 2005; Verma 
et al., 1997). 
 
In addition to being highly specific and processive in chain elongation, UBE2N/UEV1a (K63), 
UBE2K (K48), UBE2R1 (K48), UBE2D3 (promiscuous, predominantly K48) and UBE2S (K11), 
rank as the most abundant E2 enzymes found in human cels (Stewart et al., 2016 ). Regulation 
of these very abundant and eficient E2s may come from limited availability of 
monoubiquitinating E2s, free ubiquitin, and interacting E3 ligases.  
 
1.3 E3 Ubiquitin Ligases 
 
The transfer of ubiquitin from the charged E2 to a specific substrate is catalyzed by E3 ligases. 
There are three types of E3 ligases: HECT, RING, and RBR, which difer in the mechanism by 
which they facilitate the transfer of ubiquitin (Berndsen and Wolberger, 2014; Zheng and 
Shabeck, 2017). HECT E3 ligases contain a catalytic cysteine that transfers the ubiquitin from a 
charged E2 and forms a thioester linkage with the C-terminus of the donor ubiquitin, E3~Ub 
(Pickart, 2001; Wang and Pickart, 2005). The substrate ε-lysine then atacks the thioester 
linkage on E3~Ub, which transfers the ubiquitin molecule to the substrate. A majority of E3s 
belong to the RING family, which contain a RING or U-box domain that coordinates two zinc 
atoms in order catalyze the transfer of ubiquitin from E2 to substrate without any E3 catalytic 
activity (Deshaies and Joazeiro, 2009; Metzger et al., 2014). RING E3s do not form a thioester 
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ubiquitin intermediate like the HECT ligases, but instead act as a mediator to bring the charged 
E2 and the target substrate in close proximity to one another (Plechanovov et al., 2012). The 
RING domain contains a conserved cysteine and histidine residue that are structuraly aranged 
in a cross-brace configuration to coordinate zinc atoms (Borden, 2000; Freemont, 2000; 
Lovering et al., 1993). The RING domain provides a globular platform to mediate protein-protein 
interactions (Borden, 2000). Finaly, RBR E3 ligases contain features of both HECT and RING 
E3s. RBRs form a E3~Ub through a catalytic cysteine, as do HECT E3 ligases, and recruit the 
charged E2 by a RING domain (Sprat et al., 2014). 
 
The smal ubiquitin-like modifier (SUMO) protein functions similarly to ubiquitin as a post-
translational modification (Hay, 2005). RNF4 is a mammalian RING E3 that belongs to the 
SUMO-Targeted Ubiquitin Ligase (STUbL) family of E3s that ubiquitinate poly-SUMO substrates 
(Lalemand-Breitenbach et al., 2008; Sun et al., 2007; Tatham et al., 2008; Uzunova et al., 
2007). RNF4 contains four N-terminal SUMO interacting motifs (SIMs) that bind to poly-SUMO 
as wel as C-terminal RING domain that contacts both the E2 and donor ubiquitin in E2~Ub 
(Moilanen et al., 1998; Tatham et al., 2008). In response to arsenic therapy, Promyelocytic 
Leukemia Protein (PML) is modified by a poly-SUMO chain that recruits RNF4 and is 
subsequently ubiquitinated and degraded (Lalemand-Breitenbach et al., 2008; Tatham et al., 
2008). This reaction shows varying degrees of processivity depending on the interaction 
between the E2 enzyme and the RNF4 RING domain (DiBelo et al., 2016). 
 
1.4 Deubiquitinating Enzymes  
 
Deubiquitinating enzymes (DUBs) are specialized proteases that remove the ubiquitin 
modification and disassemble polyubiquitin chains. DUBs recognize ubiquitin and cleave the 
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isopeptide linkage that connects the ubiquitin C-terminus to the lysine ε-amino of either a 
protein substrate or another ubiquitin molecule. The ubiquitin whose C-terminus directly 
contacts the active site of the DUB is refered to as the distal ubiquitin, while ubiquitin molecule 
containing the lysine that connects to C-terminus of the distal ubiquitin is refered to as the 
proximal ubiquitin. In humans there are ~100 diferent DUBs that are implicated in diverse 
biological pathways including ubiquitin processing, cel cycle regulation, neurodegenerative 
diseases, inflammatory responses, and tumor migration and growth (Clague et al., 2012; Clague 
et al., 2019; Turcu et al., 2009). DUBs are divided into seven diferent families, classified based 
on the type of catalytic domain. Six of the DUB families are cysteine proteases: ubiquitin specific 
proteases (USP), ovarian tumor proteases (OTU), ubiquitin C-terminal hydrolases (UCH), 
Josephins (MJD), MINDY, and ZUP1 (Burows and Johnston, 2012; Clague et al., 2019; Haahr 
et al., 2018; Komander et al., 2009; Mevissen et al., 2013; Turcu et al., 2009). The remaining 
DUB family is exemplified by the zinc-dependent Jab/MPN (JAMM) metaloprotease (Shrestha 
et al., 2014; Turcu et al., 2009). Just as there are many diferent types of ubiquitin linkages, 
chain length, and types of modifications, there are equaly abounding possibilities for ubiquitin 
recognition and the specificity of deubiquitinating enzymes. 
 
DUBs must be able to navigate the intricacies of the ubiquitin system—diferentiating between 
mono- and poly-ubiquitinated species and discriminating between cleaving one linkage type 
over another. Some DUBs, like MINDY, act as exonucleases, as they preferentialy process a 
chain starting from the distal ubiquitin (Abdul Rehman et al., 2016). Others are endonucleases 
that cleave preferentialy within a chain. USPs comprise the largest family of deubiquitinating 
enzymes, with over 50 known USP DUBs in humans (Clague et al., 2019; Nijman et al., 2005). 
These DUBs vary significantly in catalytic rate and show modest preference for linkages types, 
with only USP30 and CYLD showing specificity for cleaving K6 and both M1 and K63 chains, 
 9 
respectively (Faesen et al., 2011; Ritorto et al., 2014). By contrast, members of the OTU family 
of DUBs are typicaly quite specific for diferent chain types, with diferent family members 
exhibiting distinct chain preference (Table 1.2). The OTU DUBs, OTUB1, OTUD4, and A20 are 
specific for cleaving K48 linked chains, while OTUD1 and phosphorylated OTUD4 cleave K63 
chains (Mevissen et al., 2013; Wang et al., 2009). Cezanne cleaves K11 chains, TRABID 
cleaves K29 and K33 chains, and OTULIN cleaves linear M1 (Bremm et al., 2010; Evans et al., 
2003; Mevissen et al., 2013; Tran et al., 2008). Some deubiquitinating enzymes from the other 
DUB families also show specificity for particular chain types. MINDY cleaves K48-linked chains 
(Abdul Rehman et al., 2016), MYSM1 (MJD) and BAP1 (UCH) remove monoubiquitin from 
histones (Panda et al., 2015; Sahtoe et al., 2016), and ZUP1 cleaves K63-linked chains (Haahr 
et al., 2018). Linkage specificity is either encoded by the catalytic domain or is determined by 
the interactions between the DUB and a protein interactor. 
 
1.5 Deubiquitinating enzyme activity can be modulated by forming 
complexes with other proteins 
 
Many DUBs are found in complex with other proteins (Sowa et al., 2010), which in some cases 
have been shown to modulate DUB activity (Venti and Wilkinson, 2008). For example, USP1 
must complex with a non-catalytic subunit, UAF1, in order to deubiquitinate key regulators, 
FANCD2 and FANCI, in the DNA damage response (Cohn and D’Andrea, 2008). USP14, 
UCH37, and Rpn11 al need to associate with the 26S proteasome in order to exhibit any 
deubiquitinating activity (Venti and Wilkinson, 2008). In fact, a screen using MALDI-TOF Mass 
spectrometry of basal isopeptidase activity for 42 DUBs revealed that the majority of these 
enzymes in their apo form had litle to no catalytic activity (Ritorto et al., 2014), raising the 
possibility that many of them may rely on partner proteins that increase their activity. 
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Several DUBs have been found to associate with E3 ligases and, less frequently, E2 enzymes 
(Sowa et al., 2010). A few of these DUB:E3 ligase pairs have a direct role in tumor progression 
and growth. For example, the DUB:E3 pair, BAP1 (UCH):BRCA1, is implicated in breast and 
lung cancer growth (Jensen et al., 1998) and USP2a:Mdm2 is directly linked to apoptosis and 
the development of prostate cancer (Priolo et al., 2006). Other DUB:E3 pairs that serve to 
regulate the catalytic activities of both enzymes include: USP4:Ro52, USP7:Mdm2, 
USP20:VHL, USP8:Nrdp1, USP33:VHL, and USP28:FBW7alpha (Li et al., 2004; Li et al., 2002; 
Li et al., 2005; Popov et al., 2007; Venti and Wilkinson, 2008; Wada and Kamitani, 2006; Wu et 
al., 2004). For most of these pairs, it is believed that both DUB and E3 regulate one another’s 
activity. In the absence of their DUB interactors, Ro52 and Mdm2 are autoubiquitylated, which 
then signals for proteasomal degradation of these E3 ligases (Clegg et al., 2008). However, 
when bound to their respective DUBs, USP4a and USP7, autoubiquitination is inhibited 
(Meulmeester et al., 2005; Wada and Kamitani, 2006). Therefore the DUB protects the E3 from 
degradation. In turn, Ro52 afects the stability of USP4a by ubiquitylating the DUB and targeting 
it for degradation (Wada and Kamitani, 2006). For some DUB:E3 pairs determined through in 
vitro methods, such as USP7:ICP50 (Holowaty et al., 2003) and USP9:Mind bomb1 (Mib1) 
(Choe et al., 2007), the biological significance of the DUB-E3 interaction is stil not known. There 
are rarer cases of DUBs partnering with E2 ubiquitin conjugating enzymes. OTUB1 (OTU) is 
one such DUB. By binding to charged UBE2N, OTUB1 is able to sequester and prevent this E2 
from forming K63 chains at double stranded DNA breaks (Nakada et al., 2010; Wiener et al., 
2012). In turn, UBE2N has been found to stimulate the deubiquitinating activity of this DUB 
(Wiener et al., 2013). More details about this unique DUB:E2 interaction are discussed below. 
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Two essential themes concerning DUBs and their non-substrate protein binders have emerged 
from extensive studies. First, many DUBs function in complex with another non-substrate 
protein. Second, unless bound to its partner protein, DUB activity is low. The fact that so many 
DUBs are complexed with either E3 ligases or E2s demonstrates that the process of 
ubiquitylation and deubiquitylation is not a simple sequential cycle. Rather, DUBs and 
ubiquitylating enzymes work in concert with one another, regulating each other’s activity in order 
to modulate and maintain ubiquitination in response to extracelular events. 
 
1.6 OTUB1, a non-canonical deubiquitinase 
 
OTUB1 is a highly expressed OTU DUB that is specific for reversing K48-linked modifications 
(Wang et al., 2009). OTUB1 is expressed in a wide variety of diferent human tissue cels, with 
high expression in the brain (Fagerberg et al., 2014). Knocking out OTUB1 in mice results in 
embryonic lethality (Pasupala et al., 2018) and knocking down this DUB produces mice with 
reduced grip strength (Schwanhäuser et al., 2011). The most complete structure of OTUB1 is 
of a hybrid recombinantly expressed C. elegans OTU domain with a human 40 amino acid N-
terminal fusion (Wiener et al., 2013; Wiener et al., 2012) (Figure 1.4b). As the N-terminus is 
predicted to be intrinsicaly disordered in the apo state, this structure elucidated for the first time 
the α-helical fold of the N-terminus (Edelmann et al., 2008; Wiener et al., 2012). OTUB1 
contains two distinct ubiquitin binding sites, a distal and proximal site (Figure 1.4c), with the N-
terminal helix providing additional contacts for the proximal ubiquitin binding site (Wiener et al., 
2012). The structure showed the OTUB1 catalytic triad comprised of an aspartate, cysteine and 
histidine residue are positioned where the K48 linkage would be (Figure 1.4d). 
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The DUB activity of OTUB1 is implicated in numerous biological roles (Table 1.3). By stabilizing 
the transcription factors FOXM1 (Karunarathna et al., 2016; Wang et al., 2016) and ERα 
(Stanišić et al., 2009), OTUB1 is a regulator of transcriptional activation and to a more broader 
extent, is a regulator of ovarian, breast, and endometrial cancers. Additionaly, OTUB1 
deubiquitinates particular E3 ligases such as: TRAF3 & TRAF6, which are essential in 
controling virus triggered interferon induction (Li et al., 2010); c-IAP, which regulates NF-κB and 
MAPK signaling in addition to modulating apoptosis (Goncharov et al., 2013); and GRAIL, which 
regulates T-cel anergy (Soares et al., 2004). 
 
In addition to its canonical deubiquitinating activity, OTUB1 non-catalyticaly binds to and inhibits 
the ubiquitin conjugating activity of E2 enzymes. In addition to the two diferent ubiquitin binding 
sites, OTUB1 also contains an E2 binding site (Figure 1.4.c, e). The N-terminal helix not only 
provides contacting surfaces for the proximal ubiquitin but also for interacting with an E2. The 
ability of OTUB1 to inhibit E2 enzymes in a non-canonical manner was first discovered by 
Nakada et al. (Nakada et al., 2010), who found that OTUB1 suppresses K63 chain formation by 
the E2 enzyme, UBE2N, and its non-catalytic partner, UEV1a (Nakada et al., 2010; Sato et al., 
2012). In response to double stranded DNA breaks, UBE2N/UEV1a and the E3 ligase, RNF168, 
ataches K63-linked polyubiquitin to the site of damage. These regulatory chains signal for 
downstream recruitment of two repair protein complexes: RAP80-BRCA1 (Kim et al., 2007; 
Sobhian and al., 2007; Wang and al., 2007; Wu and al., 2009) and 53BP1 (Doil and al., 2009; 
Huen and al., 2007; Mailand and al., 2007), which are essential for passing the G/M checkpoint. 
Independently of its DUB activity, OTUB1 prevents UBE2N/UEV1a from transfering ubiquitin to 
the E3 (Nakada et al., 2010). Therefore, OTUB1 is a negative regulator of double stranded DNA 
response repair mechanisms. This result proved to be quite intriguing in that OTUB1 is highly 
specific for cleaving K48 linked chains and yet is able to inhibit an E2 that produces K63-linked 
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chains. In addition, OTUB1 is known to inhibit the ubiquitin conjugating activity of the E2, 
UBE2D both in vitro (Clegg et al., 2008) and in celulo (Sun et al., 2012) which afects diferent 
biological processes depending on the target (Table 1.4). OTUB1 is able to prohibit UBE2D 
from ubiquitinating a number of diferent substrates including: RAS isoforms (Baieti et al., 2016) 
p53 (Sun et al., 2012), DEPTOR, (Zhao et al., 2018), and SMAD2/3 (Herhaus et al., 2013). 
 
Structural and biochemical studies helped to elucidate the manner by which OTUB1 non-
canonicaly regulates these E2 enzymes by preferentialy binding to the charged E2 in a manner 
that depends on the N-terminus (Juang et al., 2012; Nakada et al., 2010; Wiener et al., 2012). 
Structural studies show that OTUB1 directly binds to the thioester linkage of the charged E2s, 
UBE2N (Wiener et al., 2012) and UBE2D2 (Juang et al., 2012; Wiener et al., 2013). 
Additionaly, biochemical studies demonstrate that OTUB1 preferentialy interacts with E2~Ub 
versus the uncharged E2 (Nakada et al., 2010; Wiener et al., 2013; Wiener et al., 2012). By 
binding to the charged E2, OTUB1 prevents ubiquitin transfer from the E2 to substrates (Juang 
et al., 2012; Wiener et al., 2013) (Figure 1.4e). By binding to UBE2N~Ub, OTUB1 not only 
stops ubiquitin transfer but also prevent UBE2N from heterodimerizing with UEV1a, which is 
necessary for K63 polyubiquitination (Wiener et al., 2012). OTUB1 also prevents the RING 
domain of both RNF168 (Nakada et al., 2010) and RNF4 (Wiener et al., 2012) E3 ligases from 
binding to the E2 as OTUB1 and RINGs share the same site. Structural studies also indicate 
that this mode of E2 inhibition is dependent on an alosteric conformational change initiated by 
ubiquitin binding to the proximal site on OTUB1, which triggers conformational changes in the 
proximal ubiquitin-binding site and drives formation of the α-helical N-terminus (Wiener et al., 
2012). The N-terminus provides additional contacting surfaces for both the E2 and the proximal 
ubiquitin binding site, which favors interaction with E2~Ub. Removing the N-terminus completely 
abolishes OTUB1’s ability to non-canonicaly inhibit UBE2N (Nakada et al., 2010). Binding 
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preferentialy to the charged E2 is corelated with increasing concentrations of free Ub (Wiener 
et al., 2012). 
 
1.7 Regulation of both canonical and non-canonical activities for OTUB1 
 
Post-translational modifications of OTUB1, ubiquitination, hydroxylation, and phosphorylation, 
regulate its activity and may have implications for its non-canonical E2 inhibition (Table 1.4). 
When investigating the role of OTUB1 in inhibited UBE2D ubiquitination of p53, the Dai lab (Li et 
al., 2014) noted a higher molecular weight form of the DUB that coresponded to ubiquitinated 
OTUB1. Systematic mutational analysis, in which each lysine on OTUB1 was mutated to an 
arginine, revealed that OTUB1 can be ubiquitinated at either residue 59 or 109. Substitution of 
al lysines with arginine (K0) rendered OTUB1 unable to inhibit p53 ubiquitination. It is unclear 
whether it is the lack of lysines or the lack of ubiquitinated OTUB1 that abolishes the non-
canonical inhibition of UBE2D. In addition, OTUB1 can be hydroxylated at N22, which restricts 
the DUB interactome (Scholz et al., 2016). Although hydroxylation does not change the 
isopeptidase activity of OTUB1, Scholtz et al. predict that this modification may afect non-
canonical inhibition, as the site of hydroxylation is located on the N-terminus which contacts the 
thioester of the charged E2. Serine 16, also located on the N-terminus of OTUB1, is 
phosphorylated by casein kinase 2 (CK2) (Herhaus et al., 2013). Although phosphorylation did 
not afect either the DUB nor the non-catalytic activities of OTUB1, the modification does signal 
for nuclear localization of the DUB. In response to DNA damage, chromatin is ubiquitinated, so 
phosphorylating OTUB1 may sequester it in the cytosol. Recent studies have revealed that 
OTUB1 can be conjugated with the ubiquitin-like modifier, FAT10 (Bialas et al., 2019). 
Covalently linking FAT10 to OTUB1 targets the DUB for proteasomal degradation; however, 
when OTUB1 noncovalently interacts with FAT10, it increases the DUB activity in cleaving both 
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K48 diUbiquitinand Ub-AMC. It is unclear to what extent these post-translational modifications 
have an efect on either the deubiquitinating and non-catalytic activities of OTUB1.  
 
1.8 The cross-regulatory complex of OTUB1: E2 enzymes 
 
When in complex, OTUB1 and its E2s cross-regulate one another’s activity. I previously 
discussed how OTUB1 non-canonicaly inhibits UBE2N and UBE2D enzymes from conjugating 
ubiquitin. In turn, binding of diferent E2s has implication for the DUB activity of OTUB1. 
Surprisingly, in vitro kinetic studies that assayed the isopeptidase activity of OTUB1 on K48 
diUbiquitinshowed that the DUB activity of OTUB1 is broadly stimulated in the presence of 
UBE2D1, UBE2D2, UBE2D3, UBE2N, and UBE2E1 (Wiener et al., 2013). A detailed kinetic 
analysis of the efects of UBE2D2 showed that this E2 robustly stimulated the isopeptidase 
activity of OTUB1 for cleaving K48 linked diUbiquitin (K48 diUb), with a dramatic lowering of KM 
from 120 μM to 3.4 μM, and no overal efect on kcat (Wiener et al., 2013). With no change to 
kcat, the E2 does not afect the turnover rate for OTUB1 to convert diUbiquitininto monoubiquitin. 
The physiological consequence of lowering the KM suggests that the DUB activity of OTUB1 is 
more active at ubiquitin concentrations that it wil likely encounter in the cel. Another interesting 
result from this DUB study showed that UBE2N only weakly stimulated the cleaving ability of 
OTUB1. Since OTUB1 eficiently inhibits UBE2N from heterodimerizing with its non-cognate 
UEV1a and sequesters the E2 from making K63 linked chains, it is interesting that UBE2N only 
modestly afects OTUB1. The in vitro kinetic assay also established UBE2W as an interacting 
partner that can stimulate the catalytic activity of OTUB1 (Wiener et al., 2013). UBE2W is a 
highly disordered E2 that predominantly monoubiquitinates the N-terminal amine (Scaglione et 
al., 2013). In contrast with the other E2 enzymes that stimulate OTUB1 DUB activity in vitro, 
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UBE2W has not been identified as an in vivo OTUB1. The biological significance of stimulated 
DUB activity in the presence of an E2 is unknown. 
 
 Although OTUB1 is specific for cleaving K48 chains, it interacts with E2 enzymes that are from 
diferent classes and produce various chain types. One similarity for al seven diferent E2s is 
that they al interact with the three diferent types of E3 ligases: RING, HECT, and RBR (Stewart 
et al., 2016 ). From non-catalytic inhibition for some of these E2s, together with the marked 
stimulated DUB activity in the presence of these same E2s, a model for cross-regulation 
emerges. The OTUB1:E2 cross-regulation occurs when OTUB1 regulates the ubiquitin 






Mass spectrometry and proteomic studies revealed that OTUB1 interacts with seven diferent 
E2s in celulo: UBE2D1, UBE2D2, UBE2D3, UBE2N, UBE2E1, UBE2E2, and UBE2E3 (Nakada 
et al., 2010; Sowa et al., 2010) (Table 1.5). I sought to study and understand the cross-
regulatory complex, OTUB1:E2, through in vitro biochemical assays and structural methods. 
The Wolberger lab found that the isopeptidase activity of OTUB1 is enhanced over a broad 
range of stimulation. I wondered what molecular mechanisms were governing these diferences 
in stimulation. Since kinetic parameters for DUB activity were already established in the 
presence and absence of UBE2D2 (3.4 μM to 120 μM respectively) (Wiener et al., 2013), I 
wanted to fil in the gaps and determine kinetic parameters for the remaining OTUB1-interacting 
E2s. Some of these OTUB1-interacting E2s are known to be inhibited by OTUB1. As discussed 
earlier, OTUB1 non-canonicaly sequesters E2s like UBE2N, UBE2D2, and UBE2D3 from 
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interacting with their coresponding E3 ligases (Chen et al., 2016; Nakada et al., 2010; Sato et 
al., 2012; Sun et al., 2012). Non-catalytic inhibition of these E2s was observed using diferent 
E3 partners, means of analysis (Western blots vs Coomasie stain), and even diferent versions 
of OTUB1 were used. In order to make direct comparisons of inhibition for each E2, those 
already studied and the additional four remaining OTUB1-interacting E2s, I performed gel-based 
inhibition assays which brought about a more cohesive manner for analysis. These gel-based 
assays helped to answer the question, at what concentration is OTUB1 able to successfuly 
sequester the E2? From the stimulation and inhibition parameters I can beter understand the 
mode of regulation that governs the OTUB1:E2 cross-regulatory complex. 
 
The demographics of the ubiquitin system in the cel play a major role in understanding why the 
OTUB1:E2 complex is so important for regulating both ubiquitylation and deubiquitylation. 
OTUB1 is one of the most abundant DUBs with an estimated amount of > 4 x 106 copies, 
roughly 2.93 μM, found in human cels (Clague et al., 2015). UBE2N / UEV1 and UBE2D3 rank 
among the highest abundant E2s in both mice and human cels with relative concentrations of 
1.3 μM and 1.7 μM, respectively (Kulak et al., 2014; Schwanhäusser et al., 2011). The fact that 
in the presence of UBE2D2, the KM of OTUB1 drops 34-fold, led to the hypothesis that the E2 
primarily serves to lower the afinity of OTUB1 for K48 diUbiquitinto concentrations to a more 
physiological concentration (Wiener et al., 2013). Although the concentrations of K48 
diUbiquitinis unknown, it is more likely that OTUB1 wil encounter 3.4 μM rather than 120 μM of 
this substrate in the cel. I are curious to see how the balance between the two diferent 
activities: canonical DUB activity and non-canonical E2 inhibition, compare with actual celular 
concentration for these diferent proteins in the cel. 
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This thesis is divided into studying the two sides of the cross-regulatory complex, OTUB1:E2. 
Chapter 2 focuses on the DUB stimulation by E2 partners and Chapter 3 In this chapter, I 
describe the in-depth biochemical studies used to establish binding and FRET-based kinetic 
parameters to define the molecular mechanisms responsible for E2 facilitated stimulation of 
OTUB1’s DUB activity. The folowing are determined: binding afinities between the E2 and 
OTUB1, efective concentrations (EC50s) for E2 facilitated stimulation, and kinetic constants (KM 
and kcat) in the absence and presence of the diferent OTUB1-interacting E2s. Chapter 3 
analyzes the role that OTUB1 plays in non-catalyticaly inhibiting the seven diferent OTUB1-
interacting E2s through gel based biochemical assays. In this thesis, I standardize the analysis 
for OTUB1 facilitated inhibition for al seven E2s so that al activity is comparable, and I use the 
same gel based assay, E1 and E3, and concentrations of OTUB1. Chapter 3 summarizes the 
strategies employed to obtain a structure of OTUB1 with one of its E2 partners, UBE2E1. 
Curently, the only structures of OTUB1 complexed with an E2 are either with UBE2D2 or with 
UBE2N, both of which are Class I E2s. UBE2E1 is a Class II E2 and although crystals 
containing both ful length OTUB1 and UBE2E1 were obtained, high resolution crystalography 
data remained elusive.  
 
OTUB1 is involved in several diferent biological pathways that are directly linked to the 
progression and growth of various cancers (Table 1.3 & 1.4). OTUB1 specific inhibitors may be 
developed to help ail or treat many of these diferent cancer-promoting pathways. DUBs have 
frequently been used as drug targets as the active cysteine react readily with most inhibitors in 
order to reduce catalytic activity (D'Arcy et al., 2015; Farshi et al., 2015; Ndubaku and Tsui, 
2015; Wang et al., 2017). Since OTUB1 uniquely possesses both catalytic and non-canonical 
activities, both serve as potential targets to modulate overal activity of this DUB. Some 
inhibitors, like N-ethylmaeleimide, have been shown to target active site cysteine and diminish 
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catalytic activity of OTUB1 (Balakirev et al., 2003). The inhibitor, Ubc.B1.1, ataches to the distal 
ubiquitin binding and disrupts both deubiquitinating activity of OTUB1 and non-canonical E2 
inhibition (Ernst et al., 2013; Gorelik and Sidhu, 2016). Indeed, as more information about the 
molecular mechanisms that govern the OTUB1:E2 cross-regulatory are more studied, I wil 












Chapter 2 Select E2s stimulate the DUB activity of OTUB1 
 
2.1  Introduction 
 
Although OTUB1 is a wel-established deubiquitinase, relatively litle is known about the 
biological role of its DUB activity (Goncharov et al., 2013; Karunarathna et al., 2016; Li et al., 
2010; Soares et al., 2004; Stanišić et al., 2009; Wang et al., 2016), as compared to its role in 
non-canonical inhibition of E2 enzymes (Baieti et al., 2016; Chen et al., 2016; Herhaus et al., 
2013; Nakada et al., 2010; Zhao et al., 2018). Several studies have linked the DUB activity of 
OTUB1 to both the progression and inhibition of cancer (Table 1.4) (Goncharov et al., 2013; 
Karunarathna et al., 2016; Stanišić et al., 2009), making it important to understand how OTUB1 
is regulated in vivo. A test of OTUB1 DUB activity in the presence of eleven diferent E2s 
unexpectedly showed that a subset could stimulate isopeptidase activity (Wiener et al., 2013). 
The E2 enzymes that stimulated OTUB1 included UBE2D1, UBE2D2, UBE2D3, UBE2N, and 
UBE2E1, which had previously been identified as OTUB1-interacting E2s in vivo and whose 
ubiquitin conjugating activity is non-canonicaly inhibited by OTUB1 (Nakada et al., 2010; Sowa 
et al., 2010). Interestingly, UBE2W, which was not known to interact in vivo with OTUB1, was 
also robustly stimulated the DUB activity of OTUB1 (Wiener et al., 2013). In qualitative time 
course assays, UBE2N only weakly stimulated the DUB activity of OTUB1 as compared with the 
stimulation by UBE2E2, which was surprising given that OTUB1 strongly inhibits the ubiquitin 
conjugating activity of UBE2N and UBE2D2 (Nakada et al., 2010). The biological consequence 
of this E2 facilitated stimulation of DUB activity remains unknown.  
 
The cross-regulatory complex, OTUB1:E2, serves a dual role in regulating ubiquitylation and 
deubiquitylation. The potential for cross-regulatory networks that govern the conditions under 
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which OTUB1 binds to its E2 partners and results in either E2 inhibition or OTUB1 stimulation 
depends on the relative kinetics and thermodynamics of the interactions, which have remained 
understudied. In the presence of UBE2D2, a robust stimulator, the KM of OTUB1 for K48 
diUbiquitinis greatly reduced from 120 μM to 3.4 μM with no change to kcat (Wiener et al., 2013). 
This result suggests that interactions between OTUB1 and UBE2D2 change the afinity of the 
DUB for K48 diUbiquitinwithout afecting the turnover rate. In this chapter, I study the molecular 
mechanisms responsible for this KM change by measuring the changes in DUB activity in the 
presence of the various OTUB1-interacting E2s using a FRET-based assay. I determine the 
kinetic parameters for the other OTUB1-interacting E2s and show that DUB stimulation occurs 
over a range of enzyme concentrations that corespond to those measured in cels(Kulak et al., 
2014; Schwanhäusser et al., 2011). Understanding the mechanisms that control cross-





2.2.1 OTUB1-interacting E2s partners al stimulate the DUB activity of OTUB1 to varying 
degrees 
 
Proteomic studies identified UBE2E2 and UBE2E3 as binding partners of OTUB1 in pul-down 
experiments from whole cel extracts (Nakada et al., 2010), but the consequences of OTUB1 
binding to these E2 enzymes has not been explored. I therefore assayed the relative ability of 
UBE2E2 and UBE2E3 to stimulate the DUB activity of OTUB1 as compared to the remaining E2 
partners, UBE2E1, UBE2N, and the three UBE2D enzymes. I also assayed the interaction 
between UBE2W and OTUB1; although this E2 was not determined to be an in vivo partner, in 
vitro methods found that UBE2W can stimulate the DUB activity of OTUB1 (Wiener et al., 2013). 
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Using a fluorescence resonance energy transfer (FRET) deubiquitylation assay in which 
fluorescence of an internaly quenched fluorophore on TAMRA-labeled K48 diUbiquitin (diUb) 
increases when OTUB1 cleaves the isopeptide linkage, I found that UBE2E2 and UBE2E3 only 
modestly enhanced OTUB1 DUB activity (Figure 2.1). Taking the initial rates from this FRET 
experiment I determined the fold stimulation in the presence of each E2 (Figure 2.1.b). The 
UBE2D family of enzymes had the elicited the most stimulated response with the robust 
stimulator, UBE2D2, having a 26-fold enhancement to DUB activity. UBE2N stimulated 
isopeptidase activity weakly, with an enhancement of less than 10 fold. As compared to the 
other E2s, the degree of stimulation observed for UBE2E2 and UBE2E3 was the weakest for al 
the E2s studied, with less than a five-fold enhancement in DUB activity. 
 
2.2.2 E2-dependent stimulation of OTUB1 is not due to diferences in binding afinity  
 
Formation of both repressive and active OTUB1-E2 complexes are governed, in part, by the 
intrinsic afinity of OTUB1 for each of its in vivo E2 partners. To assess the contribution of 
intrinsic afinity of diferent OTUB1-E2 pairs to E2 repression and OTUB1 activation, I measured 
equilibrium dissociation constants (Kd) for OTUB1 binding to UBE2D1, UBE2D2, UBE2D3, 
UBE2N, and UBE2E1 using isothermal titration calorimetry (ITC) (Figure 2.2). For these 
experiments, I used the catalyticaly inactive mutant, OTUB1 (C91S), which was also used for 
assays discussed below of OTUB1 binding to its K48 diUbiquitinsubstrate. I determined that the 
afinity of each E2 for OTUB1 was similar, with Kd values ranging from 3.9 – 9.3 μM (Figure 
2.2.b-c). The Kd of UBE2N binding to OTUB1 was 8.1 μM, which is consistent with previous 
studies that obtained a Kd of 7.04 μM using a fluorescence polarization assay (Wiener et al., 
2012) and Kd of 8.9 μM using surface plasmon resonance and GST-fused OTUB1 (Sato et al., 
2012). To verify that the OTUB1 C91S mutation did not afect binding to E2 enzymes, I assayed 
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binding of a subset of the E2s, UBE2D1 and UBE2D3, to wild-type OTUB1 and found no 
significant diference in Kd values (Figure 2.3). I was unable to measure the Kd for the 
interactions between OTUB1 and UBE2E2 or UBE2E3, as the two proteins precipitated in the 
ITC cel and yielded unreliable results. 
 
As a control, I also tested binding of OTUB1 to other E2s that have not been recognized as an 
interacting partner in vivo. As expected, I did not detect any binding between OTUB1 and 
Cdc34, which selectively forms K48 chains (Figure 2.4). I also looked at binding between 
OTUB1 and Ube2g2, an E2 that predominantly forms K48 linked chains and is implicated in 
endoplasmic reticulum-associated protein degradation (Kostova et al., 2007). I found no 
observable binding between these two proteins, which is interesting given that in vitro studies 
have identified Ube2g2 as an interactor for OTUB1, one that was not previously determined 
through afinity capture mass spectrometry (Scholz et al., 2016). Overal, OTUB1 bound al E2 
partners with similar afinities. Diferences in DUB stimulation cannot simply be explained by 
binding between these two sets of factors. 
 
2.2.3 E2 half-maximal stimulation of OTUB1, EC50s, match intracelular concentrations  
 
As shown in Figure 2.1 and in a previous study (Wiener et al., 2013), the stimulatory efect of 
diferent E2 partners varies. Since OTUB1 binds with similar afinity to al its E2 partners, I 
sought to understand the mechanism that produced a broad range of stimulation on DUB 
activity. To further characterize the efect of E2 binding to OTUB1 on DUB activity, I assayed 
OTUB1 activity as a function of E2 concentration to determine a half-maximal stimulatory 
response dose for 50% enhancement (EC50). Using a FRET-based assay, I measured and 
tracked the signal over time in order to establish rates of isopeptidase activity for OTUB1 over 
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increasing log-base 10 concentrations of E2 (0.001 nM – 100 μM) (Figure 2.5.a). I found that 
the E2 concentration to elicit a stimulatory response was between 0.8 – 10.9 μM. Of al seven 
OTUB1-interacting E2s that I studied, UBE2N had the lowest EC50, (0.8 μM) therefore OTUB1 
requires less of UBE2N to exhibit stimulated activity. This result was very surprising given that 
UBE2N has proven in previous experiments (Wiener et al., 2013) and in my FRET E2 panel 
(Figure 2.1) to be a weak DUB stimulator. The highest half-maximal stimulation occured in the 
presence of both UBE2E2 and UBE2E3, with EC50 concentrations of 10.9 and 10.7 μM, 
respectively. The efective concentrations for half-maximal stimulation by the UBE2D family of 
enzymes was in the range of 1.5 – 3.9 μM. The EC50 for UBE2D2 was determined to be 3.8 μM, 
whereas a previous study determined the EC50 to be 0.5 μM using a gel-based assay (Wiener et 
al., 2013). It is possible that this large discrepancy may be atributed to the method obtaining 
these EC50 values. Interestingly though, the EC50s determined for UBE2N and UBE2D3 
matches the intracelular concentrations of those found in human cels (Kulak et al., 2014; 
Schwanhäusser et al., 2011) which are 1.3 μM for UBE2N and 1.7 μM for UBE2D3. Taken 
together, our calculated EC50s suggest that these E2 partners can regulate OTUB1 activity over 
a physiologicaly relevant range of concentrations. 
 
I next asked whether the binding of the E2 has a cooperative efect on OTUB1 activity on diUb. 
The Hil slope, or Hil coeficient, is a measure of cooperativity among multiple ligand binding 
sites (Prinz, 2010; Weiss, 1997). In the context of our biochemical studies, it estimates how 
binding of the E2 can change the afinity of OTUB1 for K48 diUb. Slopes > 1 signify positive 
cooperativity, slopes < 1 indicate negative cooperativity, and for slopes = 1, binding of K48 
diUbiquitinis independent binding to the E2. I fit the data using the “log-agonist versus 
response—variable slope” program within GraphPad Prism version 5.0, which calculates both 
EC50s and Hil Slopes. As shown in Figure 2.5.b, the calculated Hil Slopes were 1.2 ± 0.4 for 
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UBE2D1, 1.8 ± 0.6 for UBE2D2, 2.2 + 0.6 for UBE2D3, 0.7 ± 0.2 for UBE2N, 1.5 ± 0.5 for 
UBE2E1, 1.1 + 0.5 for UBE2E2, and 0.7 ± 0.3 for UBE2E3. I observe a Hil slope >1 for al E2s 
except UBE2N and UBE2E3. The Hil slope for UBE2E3 with the eror is 0.7 ± 0.3 placing 
coeficient closer to one. However, even with the eror, UBE2N (0.7 ± 0.2), is stil less than one. 
Comparing the slopes for UBE2D3, the largest Hil coeficient to the least, UBE2N, I saw a stark 
contrast in the curvature. It is possible that binding of the UBE2N can reduce the afinity of 
OTUB1 for K48 diUb. 
 
2.2.4 Binding an E2 partner raises afinity of OTUB1 for K48 diUb 
 
I next sought to quantify the degree of stimulated DUB activity in the presence of these OTUB1-
interacting E2s. A previous study reported a marked stimulation of the isopeptidase activity in 
the presence of UBE2D2. The KM, Michaelis Menten constant, of OTUB1 for K48 diUbiquitinwas 
lowered 34-fold, from 120 μM to 3.4 μM, in the presence of UBE2D2 respectively (Wiener et al., 
2013). Although there was a dramatic reduction in KM, no change in kcat was detected. In terms 
of this experiment, KM is the amount of K48 diUbiquitinneeded for OTUB1 to reach a half 
maximal reaction rate and kcat describes the turnover rate for OTUB1 to convert K48 
diUbiquitininto mono-ubiquitin. With the exception of UBE2D2, kinetic constants have not been 
determined for the remaining E2 partners of OTUB1. To quantify the degree of stimulation by 
other E2s, I employed the FRET assay and tracked the cleavage of FRET-K48 diUbiquitinover 
time in the presence and absence of saturating concentrations of E2s, UBE2D1, UBE2D2, 
UBE2D3, UBE2N, and UBE2E1 (Figure 2.6). For these assays, I used saturating 
concentrations of each E2 (10 μM) since this is 0.5 to 10 fold higher than the half-maximal 
efective concentrations that I determined (Figure 2.5). In addition, this FRET assay difered 
from the assay used to measure EC50s in that the substrate concentration was a ratio of FRET-
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K48 diUbiquitinto unlabeled K48 diUb. I kept a constant amount 400 nM FRET-K48 
diUbiquitinfor each experiment and added the remaining amounts of unlabeled substrate. From 
this FRET assay I determined kinetic parameters: KM and kcat. 
 
Our results showed that, in the absence of an E2, the KM of OTUB1 for K48 diUbiquitinwas 102 
μM and the kcat was 0.03 s-1 . Within eror, these values are comparable to previous 
measurements, with a KM of 78 μM (Wang et al., 2009) and a KM of 120 μM with a kcat of 0.034 
s-1 (Wiener et al., 2013), both of which were determined using diferent methods. I found the Km 
of OTUB1 for K48 diUbiquitinin the presence of members of the UBE2D family of proteins, 
UBE2D1 (KM of 11 μM), UBE2D2 (KM of 6.6 μM), and UBE2D3 (KM of 13 μM), was lowered to 
the greatest degree. I note that the decrease in the KM of OTUB1 in the presence of UBE2D2 
was just 16 fold, from 102 μM to 6.6 μM, as compared to the 34-fold decrease that was 
previously determined (Wiener et al., 2013). The KM in the presence of UBE2N was 24.1 μM. 
UBE2N has been qualitatively described as a mild stimulator and our results depict exactly that. 
Stimulation of DUB activity was weakest in the presence of UBE2E1, which lowered the KM of 
OTUB1 for substrate to just 64.3 μM. I did not quantify changes in DUB activity in the presence 
of either UBE2E2 or UBE2E3. From the DUB stimulation panel in Figure 2.1, I predicted that 
the any enchancement by either UBE2E2 or UBE2E3 would be significantly minimal. 
Additionaly, for each experiment I calculated the kcat/KM , which is a measurement of catalytic 
eficiency, as it takes into account both substrate binding and product formation (Figure 2.6.b). 
Since kcat was largely unchanged, diferences in catalytic eficiency resulted in KM diferences. In 
the absence of an E2, the catalytic eficiency of OTUB1 converting K48 diUbiquitininto 
monoubiqiutin is 292.7 M-1s-1. This rate was largely enhanced in the presence of UBE2D2, from 
292.7 M-1s-1 to 5000 M-1s-1, whereas UBE2N showed a mild increase with a coresponding 
kcat/KM of 1452.3 M-1s-1. 
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In steady state conditions, where the rate of converting K48 diUbiquitininto monoubqiutin is 
significantly smaler than the rate of OTUB1:K48 diUbiquitincomplex formation, the Michaelis 
Menten constant KM is directly proportional to the equilibrium dissociation constant, Kd. In the 
presence of an E2, the KM changes but the kcat remains largely unchanged, thus the E2 serves 
to directly afect the binding afinity between OTUB1 and K48 diUb. I utilized ITC to test if the 
presence of an E2 partner increases the afinity of OTUB1 for its substrate, K48 diUb. Although 
the isopeptidase activity of OTUB1 for K48 diUbiquitinwas fuly characterized to be weak, with a 
coresponding KM of ~100 μM (Wang et al., 2009; Wiener et al., 2013), and the overal binding 
afinity between OTUB1 and K48 diUbiquitinis believed to be low (Edelmann et al., 2008), the 
interaction has not been quantified. I first measured the binding afinity of OTUB1 for K48 
diUbiquitinusing ITC (Figure 2.7.a). I used a catalytic mutant of OTUB1 (C91S) when titrating in 
K48-diubiquitin to ensure that the Kd I measured was not a function of both binding and 
simultaneous cleavage of the substrate. I found that OTUB1 (C91S) weakly binds to its 
substrate, with a Kd of 80 μM. The high KM of OTUB1 for K48 diUbiquitinis corelated to a weak 
afinity between these two proteins. 
 
Next, I asked whether the binding afinity of OTUB1 for K48 diUbiquitinchanges in the presence 
of saturating concentrations of E2 (150 μM) in both the cel and the syringe. This method 
alowed us to directly measure K48 diUbiquitinbinding to the OTUB1(C91S):E2 complex without 
dilution of the E2. It is also important to note that at the concentrations used, binding between 
E2s and K48 diUbiquitinwas not observed (Figure 2.8). I determined equilibrium dissociation 
constants, between OTUB1 (C91S) and K48 diUbiquitinin presence of E2 partners UBE2D1, 
UBE2D3, and UBE2N (Figure 2.7.b-c). The presence of an E2 increased afinity of OTUB1 
(C91S) for K48 diUb, as reflected in an increase in Kd from 84 μM in the absence of an E2 to 12 
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μM in the presence of UBE2D1, 13.2 μM in the presence of UBE2D3, and 22.3 μM in the 
presence of UBE2N. These Kds are very similar to the KM values for each coresponding E2 that 
was examined using the FRET assay (Figure 2.7.c-d), indicating that the lowered KM reflects 
the increase in OTUB1 afinity for its diubiquitin substrate when this DUB is bound to an E2 
partner. Importantly, not only did I show that the OTUB1:E2 complex changes preference of 
OTUB1 for its substrate, but I also demonstrated that this phenomenon occurs over diferent 
methods, FRET assay and ITC.  
 
2.2.5 Characterization of the OTUB1:UBE2W stimulatory complex 
 
The Wolberger lab determined through in vitro methods that UBE2W stimulates the DUB activity 
of OTUB1 (Wiener et al., 2013). In contrast with the other OTUB1-interacting E2 partners, this 
unique E2 primarily initiates chain formation by preferentialy monoubiquitinates N-terminal 
amines that are intrinsicaly disordered (Scaglione et al., 2013; Tatham et al., 2013; Vital et al., 
2015). UBE2W itself contains highly disordered regions (Vital et al., 2015). In cels, UBE2W 
monoubiquitinates non N-terminal amines on TRIM5α, an E3 ligase responsible for assembling 
retroviral capsids that inhibits reverse transcription of viral genomes (Fletcher et al., 2015). 
UBE2N/UEV1a ataches K63 linked polyubiquitin chains to the monoubiquitins on TRIM5α 
(Fletcher et al., 2015). The biological role of the interaction between OTUB1 and UBE2W, 
however, is not known. 
 
I first sought to determine the binding afinity between OTUB1 and UBE2W using ITC (Figure 
2.9). After titrating increasing amounts of OTUB1 to the E2, it was not possible to determine a 
reliable binding isotherm from the data. At pH 7.5, which is the pH at which al other OTUB1:E2 
binding assays were performed, the heats became endothermic as more and more OTUB1 was 
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titrated in. I repeated this experiment again and this time removed the contents of the cel after 
the experiment had concluded (Figure 2.9.b). I found that both UBE2W and OTUB1 were 
precipitating and both proteins were found in the pelet. It is possible that the constant spinning 
in the cel caused UBE2W to crash out. I atempted to redo this experiment once again but 
changed the pH from 7.5 to 7. Since the pI of UBE2W is 7.8, I speculated that the pH in the 
previous experiment was too close to the pI and maybe was causing the protein to precipitate. 
However, changing the pH did not improve the behavior of the proteins in the calorimeter. 
 
Since UBE2W is able to stimulate the DUB activity of OTUB1 within a range similar to other E2 
partners (Figure 2.1), I examined how this E2 afects the kinetics of OTUB1. First, I determined 
the EC50 and found that the concentration of UBE2W at which half-maximal stimulation of 
OTUB1 occurs is 6.7 μM (Figure 2.10.a). As compared to the EC50 values for other E2s that 
interact with OTUB1, the EC50 for UBE2W is closest to that of the UBE2E family of enzymes, 
4.6-10.9 μM (Figure 2.5). This result indicates that even though UBE2W strongly stimulates 
OTUB1 as compared to the other E2s, stimulation requires a higher concentration of UBE2W. I 
also determined the KM and kcat for OTUB1 in the presence of UBE2W (Figure 2.10.b-c). The 
KM was 22.7 μM and the kcat was 0.0047 s-1. Based on the stimulation panel, I expected the KM 
change for UBE2W to be between the KMs for UBE2D enzymes and UBE2N, which it was. 
However, I did not expect to see a diference in kcat, 0.047 s-1, since this change was not 
observed for the other OTUB1-interacting E2s, which al maintained a kcat around 0.033 s-1 
(Figure 2.6). The kcat for OTUB1 in the presence of UBE2W is almost twice that in the absence 
of an E2 (Figure 2.10.b and c). To get a beter understanding of how this change in kcat afects 
the DUB activity of OTUB1, I calculated catalytic eficiency in the presence of UBE2W (kcat / KM = 
2070.5 M-1 s-1) and compared this value to ones determined for UBE2D2 (5000 M-1 s-1), UBE2N 
(1452.3 M-1 s-1), and no E2 (292.7 M-1 s-1) (Figure 2.10.d). Given that the KM for UBE2W and 
 39 
UBE2N were very similar, diferences in fold stimulation and catalytic eficiency are atributed to 
diferences in kcat. Unlike any of the in vivo OTUB1-interacting E2s, UBE2W stimulates the DUB 
activity of OTUB1 by both afecting the binding afinity of OTUB1 for K48 diUbiquitinand by 




Previous studies had shown that, in the presence of UBE2D1, UBE2D2, UBE2D3, UBE2N, and 
UBE2E1, the isopeptidase activity of OTUB1 is broadly stimulated (Wiener et al., 2013). I first 
sought to characterize and compare the remaining in vivo OTUB1-interacting partners: UBE2E2 
and UBE2E3, to the other E2 partners and observed a broad range in enhancement. To explain 
the diferences in stimulation, I determined binding afinities between OTUB1 and select E2 
partners and found that the Kds were relatively similar. Unable to explain diferences in 
stimulation, I determined the half-maximal concentrations of E2 needed in order to elicit a 
stimulate response in DUB activity. I found that the EC50s for UBE2N and UBE2D3 matched the 
intracelular concentrations of these E2s that were determined through mass spectrometry and 
proteomic studies (Kulak et al., 2014; Michalski et al., 2011). These E2s stimulate over a 
physiological concentration. I next sought to explain diferences in stimulation through assays 
where I determined kinetic parameters, KM and kcat. 
 
Our kinetic FRET data demonstrated that binding of OTUB1 to an E2 lowers the KM for the 
substrate while the kcat remained unchanged for al in vivo E2 partners studied. These data 
suggest that forming the OTUB1:E2 complex increases the afinity of OTUB1 for K48 diUb. I 
confirmed this hypothesis using ITC where I titrated K48 diUbiquitinto OTUB1 with saturating 
concentrations of E2 in both the cel and the syringe. The Kds I measured in this experiment 
 40 
matched the KMs I had determined earlier, thus confirming that the binding of the E2 serves to 
increase afinity of OTUB1 for K48 diUb. Diferences in stimulation can be corelated with 
cooperativity, how much are the binding sites for K48 diUbiquitinchanged when binding certain 
E2s. I was most surprised by UBE2N, which has been shown to be strongly inhibited by OTUB1 
(Nakada et al., 2010; Wiener et al., 2012) and yet act as a weak stimulator for DUB activity 
(Wiener et al., 2013). The lowest EC50 I measured belonged to UBE2N, which was even more 
puzzling since smal amounts of E2 are needed to produce a stimulated efect. However, 
UBE2N also had a Hil coeficient that was less than one, which suggests negative cooperativity. 
Unlike the other OTUB1-interating E2s, the binding of UBE2N may yield a conformational 
change in OTUB1 that only slightly increases preference for K48 diUb. It is unknown whether 
this change in OTUB1 occurs near the catalytic core or the N-terminus, and mutations to either 
region would be potential experiment to try and decipher the mechanism of negative 
cooperativity for OTUB1:UBE2N. 
 
It is important to note that the kcat in the presence of UBE2W slightly increased, which I 
corelated to an increase in DUB activity and catalytic eficiency. Given that the KMs of OTUB1 
for K48 diUbiquitinin the presence of UBE2W and UBE2N were very similar, it was the change 
in kcat that produced a greater enhancement on isopeptidase activity. UBE2N is a chain 
elongator and requires other E2 enzymes, like UBE2W, to initiate chain formation (Stewart et 
al., 2016 ). It is interesting that UBE2W is a beter stimulator than UBE2N. It is possible that 
after monoubiquitinating a substrate, UBE2W binds to OTUB1, leading to stimulated DUB 
activity and an increase in monoubiquitin, which would serve as a substrate for UBE2N 
facilitated K63 chains elongation. However, given that UBE2N is functional albeit weak 
stimulator at in vivo concentrations, it is more likely that the formation of OTUB1:UBE2N 
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complex serves to sequester UBE2N from polyubiquitinating. I wil go in further detail about this 
function in the next chapter. 
 
Using the binding and kinetic that I have determined, I created an interaction scheme or 
thermodynamic cycle (Figure 2.11.a) that ilustrates OTUB1 binding to either E2 (A) or K48 
diUbiquitin(C), ultimately forming OTUB1:E2 bound to K48 diUb. Given that OTUB1-interacting 
E2s bind OTUB1 with a Kd that is tenfold lower (Kd of 3.9—9.3 μM) than that of K48 
diUbiquitin(Kd of 84 μM), it is more likely that OTUB1 wil bind first to the E2 (A) than to K48 
diUbiquitin(C). Structural studies have revealed that, in the apo state, the N-terminus of OTUB1 
is disordered (Edelmann et al., 2008; Sato et al., 2012; Wiener et al., 2012). Binding of ubiquitin 
to the distal binding site on OTUB1 triggers a conformational change that favors binding to the 
distal ubiquitin binding site by UBE2N~Ub (Wiener et al., 2012). It is possible that a similar 
conformational change in OTUB1 might be observed when first binding to an E2 partner also 
drives formation of the N-terminal helix. Folding of the N-terminal helix therefore favors binding 
to both the distal and proximal ubiquitin binding site, as evidenced by an increase in binding 
afinity for K48 diUbiquitinfrom 84 μM that dropped to a range of 6.6—64 μM. Although the 
afinity of diferent E2 enzymes was relatively similar for al those measured, it is possible that 
diferent E2 enzymes do not induce the identical the conformational change in both the distal 
and proximal ubiquitin binding sites of OTUB1. Resulting diferences in the way in which the 
OTUB1 N-terminus interacts with the proximal ubiquitin could thus potentialy account for the 
diferences in stimulated DUB activity and in afinity for K48 diUb. Given al the data I have 
colected, I was able to calculate an estimate for change in afinity that OTUB1 (D) would have 
for its E2 partners if the DUB was already bound to K48 diUbiquitin(Figure 2.11.b-c). Binding of 
K48 diUbiquitinto OTUB1 increases the afinity for the E2. Our binding and kinetic data 
elucidated the role that the E2 partners play in regulating the deubiquitinating activity of OTUB1. 
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2.1. Materials and Methods 
 
2.4.1 Cloning and mutagenesis 
 
Ub wt and Ub G77D were cloned into pET3a plasmids as previously described (Wang et al., 
2009). For Ub K48/63R, Infusion cloning was used to create both mutations in pET3a plasmid. 
Al E2 enzymes were cloned into a pET-SUMO-2 vector (Addgene) that contained an N-terminal 
His6-tag folowed by a SENP-2 protease site. The expression vector was assembled through 
Infusion ligase-free cloning. OTUB1 was cloned into a pProEx HTb (Addgene) that had an N-
terminal His6-TEV protease site. The catalytic mutant, OTUB1 (C91S), was obtained through 
site-directed mutagenesis, QuikChange mutagenesis kit (Stratagene). Al clones were 
transformed into XL1-Blue cels (Stratagene). Table 2.1 includes more details about each 
construct. 
 
2.4.2 Protein expression and purification 
 
Al proteins were expressed in E.coli Roseta-2 DE3 cels (EMD Milipore, Merck KGaA, 
Darmstradt, Germany). Cels were transformed via heat shock (42 °C for 35 secs) and plated on 
Luria Broth (LB) agar plates with 34 mg/mL Chloramphenicol and 100 mg/mL Carbenicilin. A 
smal starter growth of 50 mLs was initiated by picking 2-5 Roseta-2 DE3 colonies and placing 
into LB media with 34 mg/mL Chloramphenicol and 100 mg/mL Carbenicilin. Starter growths 
were grown at 37 °C (shaking at 250000 rpm) overnight. Large-scale cultures (1L) of M9ZB 
media (1x M9 salt mix, 0.5% NaCl, 10 g/L casamino acids, 2 mM MgSo4, 5% glycerol, and 0.5x 
Metal mix) were inoculated with 1% (v/v) overnight saturated starter cultures in addition to Chlor 
 43 
and Carb antibiotics. Cultures were grown at 37 °C (shaking at 250000 rpm) to an O.D600 ~1.5. 
At this O.D600 cels were induced with the addition of 1mM isopropyl βD-1-thiogalactopyranoside 
(IPTG) and further grown overnight (~16 hrs) at 16 °C. Cels were harvested by peleting at 
4000 x rpm at 4 °C then immediately lysed.  
 
Wild type, G77D, and K48/63R ubiquitin were purified as previously described (Wang et al., 
2009). Al E2 enzymes (UBE2D1-3, UBE2N, & UBE2E1-3) and OTUB1 proteins (wt and C91S) 
were purified by resuspending peleted Roseta cels in lysis bufer (20 mM HEPES pH 7.3, 300 
mM NaCl, 25 mM imidazole, 2 mM b-mercaptoethanol (BME). 0.1mM phenyl-methyl sulphonyl 
fluoride (PMSF) was added to cels before being lysed using a Microfluidizer (Microfluidics). The 
lysate was centrifuged (12,500 rpm at 4 °C for 25 mins) and purified using afinity 
chromatography, 5mL HisTrap (GE Biosciences). Proteins of interest were eluted using a linear 
gradient of 250 mM imidazole over 10 column volumes. To cleave the His-tag, 10 mM SENP-2 
was added to the eluted fraction, at a concentration ratio of 1:100, and dialyzed overnight at 4 
°C in lysis bufer. A second round of HisTrap purification was used to remove cleaved protein 
from SENP-2. The flow-through was colected and subjected to another round of purification as 
described below. 
 
After removing the His6-tag, al E2 enzymes except UBE2E1-3 were purified further using size 
exclusion chromatography. Fractions were concentrated down to 2 mL and run over a HiLoad 
16/60 Superdex 75 ng column with bufer: 50 mM HEPES pH 7.5, 150 mM NaCl, and 0.5 mM 
TCEP-HCl. Eluted fractions were then concentrated down to 4-10 mg/mL and stored at -80 °C. 
For UBE2E1-3 proteins, flow through fractions from the second pass through HisTrap were 
pooled and dialyzed overnight into 25 mM sodium phosphate bufer pH 7.4, 25 mM NaCl, and 
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7.5 mM b-mercaptoethanol at 4 °C. UbE2E1-3 were further purified using cation exchange 
chromatography and eluted at 100 mM NaCl. Clean fractions were dialyzed overnight at 4 °C in 
25 mM Tris bufer pH 8, 150 mM NaCl and 7.5 mM BME, concentrated to 4-10mg/mL, and 
stored at -80 °C.  
 
After the His6-tag was removed, OTUB1 and its catalytic mutant (C91S) were further purified by 
gel filtration chromatography via a HiLoad 16/60 Superdex 75 ng (GE LifeSciences) column 
equilibrated in 25 mM HEPES pH 7.6, 150 mM NaCl, and 0.5 mM tris(2-carboxyethyl)phosphine 
(TCEP). Purified OTUB1 was concentrated to 4-10 mg/mL, flash-frozen in liquid nitrogen and 
stored at -80°C until use. 
 
2.4.3 ITC experiments 
 
Al ITC experiments were performed on a MicroCal ITC200 system (Malvern) at 25 °C. The 
syringe (70 μL) titrated protein into a 300 μL sample cel. Each ITC experiment contained 19 
injections, 2 μL each for a duration of 0.8 sec over a 150 sec spacing. Al proteins measured 
were dialyzed in a bufer of 25 mM HEPES pH 7.5, 150 mM NaCl, 0.5 mM TCEP-HCl. For 
measurements between E2 (cel) and OTUB1 (C91S) (syringe), the sample cel contained 150 
μM of E2 and the syringe 1.5 mM OTUB1. For OTUB1 (C91S) interactions with K48 diUb, 1.5 
mM K48 diUbiquitinwas titrated into150 μM of OTUB1. For experiments testing the binding of 
K48 diUbiquitinto OTUB1 (C91S) at saturating concentrations of E2, 3 mM K48 diUbiquitinwas 
titrated into 150 μM OTUB1 (C91S) with a constant 150 μM of E2 was present in both the 
syringe and the cel. Heat generated due to dilution of the titrants was subtracted for baseline 




2.4.4 Generating a Standard Curve for EC50s and Kinetic assays using FRET-K48 diUb 
 
Al reactions of 30 μL were performed at 30 °C on a POLARStar Omega plate reader (BMG 
LABTECH) that measured TAMRA fluorescence (ex. 544 nm; em. 590 nm) every 5 secs over 
30 mins. Reactions contained K48 diUbiquitininternaly quenched fluorescent (IQF) TAMRA 
substrate no. 5 (LifeSensors), (FRET-K48 diUb) that ranged in concentrations from 25 - 500 nM 
to which 50 nM of OTUB1 was added. The experiment incubated in the dark at 30 °C for 1 hr to 
ensure that the substrate was fuly cleaved by OTUB1. Gain was adjusted to 1900 based on the 
fluorescence from the 500 nM FRET-K48 diUbiquitinreaction. The standard curve was obtained 
from measuring the fluorescence (AU) and ploting this against the coresponding concentration 
of FRET-K48 diUb. The data were then fited to a linear equation to obtain the slope in units of 
AU •μM−1 . This slope was therefore used for the EC50 and kinetic assays to convert (AU) into a 
measurement of μM. 
 
2.4.5 Determination of EC50s 
 
Al EC50 measurements were obtained using a POLARstar omega plate reader (BMG 
LABTECH) that monitored TAMRA fluorescence (ex. 544 nm; em. 590 nm) at a gain of 1900. 
EC50s of OTUB1 cleavage of Lys48 diUbiquitinwere measured at 30 °C in bufer containing 20 
mM HEPES, pH 7.5, 150 mM NaCl, 1 mM DTT, 0.01% BSA, and 400 nM of FRET-K48 diUb. 
Reactions (30 μL) contained specified amounts of the various E2 enzymes and were initiated by 
addition of 50 nM OTUB1. The initial rate of Lys48 diUbiquitincleavage was determined from the 
slope of the linear region of the fluorescent curves. In GraphPad Prism 5 (GraphPad Software), 
the smalest and largest values in the data set were normalized to 0 and 1 respectively. 
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Normalized data were then analyzed through Non-linear Regressions program: “log(agonist) vs 
response – Variable slope” which utilizes the folowing equation: Y=Botom + (Top-
Botom)/(1+10̂(LogEC50-X)*Hil Slope) to fit and calculate the 0.5 stimulation response. 
Experiments were done in triplicate. 
 
2.4.6 Steady-state kinetic assays 
 
Determination of Michaelis Menten kinetics were determined using a POLARStar Omega plate 
reader (BMG LABTECH) that monitored a TAMRA fluorescence (ex. 544 nm; em. 590 nm) with 
a gain of 1900. Steady-state enzyme kinetic assays were determined at 37 °C in a reaction 
bufer of 20 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM DTT, 0.01% BSA. Reactions (50 μL) in 
the presence and absence of E2 (10 μM) were initiated with the addition of 50 nM OTUB1. For 
al experiments, increasing concentrations of non-fluorescent K48 diUbiquitinwere present with 
a constant 400 nM FRET-K48 diUb. After the time assay was completed, each data point was 
multiplied by the total K48 diUbiquitinconcentration present in the initial reaction. For example, 
assays done at 100 μM K48 diUbiquitin( plus 400 nM FRET-K48 diUb), the data set was 
multiplied by 100.4. To calculate initial rates, fluorescence (AU) was converted to K48 
diUbiquitincleavage (μM ) using the equation obtained from the standard curve. The 
transformed data was ploted as a function of time and fit to a line where initial velocity 
conditions were satisfied, typicaly within the first three minutes. Initial rates were measured in 
triplicate, normalized to the enzyme concentration, ploted as a function of substrate 
concentration, and the resulting curve fit to the Michaelis-Menten equation using non-linear least 




Table 2. 1 Plasmid summary for al proteins 
Protein Plasmid Cleavage Site MW, g/mol Extinction coeficient, 1/(M cm) pI 
Ub wt pET3a NA 8564.8 1490 6.6 
Ub G77D pET3a NA 8679.9 1490 5.7 
Ub K48/63R pET3a NA 8620.8 1490 6.6 
      
UBE2D1 pETSUMO2 SENP2 17300 26930 7.1 
UBE2D2 pETSUMO2 SENP2 17460 26930 7.9 
UBE2D3 pETSUMO2 SENP2 17400 26930 7.8 
UBE2N pETSUMO2 SENP2 17140 22460 6.1 
UBE2E1 pETSUMO2 SENP2 21400 25690 8.8 
UBE2E2 pETSUMO2 SENP2 22300 25690 7.6 
UBE2E3 pETSUMO2 SENP2 22900 25690 6.7 
UBE2W pETSUMO2 SENP2 18200 24300 7.8 
      
OTUB1 wt pProEX TEV 31850 23840 4.9 













Chapter 3 Qualitative analysis of non-canonical inhibition of OTUB1-





OTUB1 is a unique DUB in that it binds to E2 enzymes and inhibits ubiquitin transfer in a 
manner that is independent of deubiquitinating activity (Baieti et al., 2016; Herhaus et al., 2013; 
Nakada et al., 2010; Sato et al., 2012; Sun et al., 2012; Wiener et al., 2012; Zhao et al., 2018). 
The non-canonical activity of OTUB1 was first discovered through its role in the double-stranded 
DNA break response (Nakada et al., 2010). OTUB1 limits accumulation of K63-linked chains on 
double-stranded DNA breaks, thus atenuating the DNA damage response once the lesion has 
been repaired (Nakada et al., 2010). OTUB1 non-catalyticaly inhibits the E2, UBE2N, by 
binding to the ubiquitin moiety in the E2~Ub thioester intermediate, thus preventing transfer of 
the ubiquitin to a substrate (Nakada et al., 2010; Sato et al., 2012). OTUB1 also occludes the 
E3 RING-binding site on the E2, thus providing an additional mechanism for inhibiting 
ubiquitination (Wiener et al., 2012). It has been shown that OTUB1 non-catalyticaly inhibits 
UBE2D proteins from ubiquitinating p53 (Chen et al., 2016; Sun et al., 2012) and SMAD2/3, 
regulators of TGFβ signaling (Herhaus et al., 2013). OTUB1 also regulates the stability of 
DEPTOR, a regulator of mTOR signaling, which is thought to occur by inhibiting atachment of 
K48-linked chains to DEPTOR by either UBE2D enzymes or another E2 (Zhao et al., 2018). In 
addition, a recent study showed that OTUB1 blocks autoubiquitylation of UBE2E1, thereby 
rescuing the E2 from proteasomal degradation (Pasupala et al., 2018). The non-catalytic roles 




Structural studies of OTUB1 have provided insights into how this DUB inhibits E2 enzymes. Like 
other members of the OTU family (Balakirev et al., 2003; Clague et al., 2012; Clague et al., 
2019), OTUB1 contains two ubiquitin binding sites, proximal and distal, which bind the two 
ubiquitin monomers, while the K48 isopeptide linkage is positioned near the catalytic cysteine 
(Figure 1.4.c and e) (Juang et al., 2012; Wiener et al., 2013; Wiener et al., 2012). (Sato et al., 
2012; Wiener et al., 2013; Wiener et al., 2012)A flexible N-terminal ubiquitin binding helix that 
forms part of the proximal site is largely disordered in the apo enzyme (Edelmann et al., 2008; 
Wiener et al., 2012) but forms an α-helix when ubiquitin is bound (Wiener et al., 2012). When 
OTUB1 forms an inhibitory complex with the E2~Ub thioester, the E2 is oriented such that the 
conjugated ubiquitin binds to the proximal site in OTUB1 (Wiener et al., 2012). Binding of the 
thioester-linked ubiquitin to the proximal site is stimulated when a second ubiquitin binds in the 
distal site, thus alostericaly increasing the afinity of OTUB1 for the ubiquitin in the proximal site 
(Wang et al., 2009; Wiener et al., 2012) 
 
I sought to characterize the OTUB1-facilitated inhibition of ubiquitin conjugating enzymes with 
which the DUB interacts. Although non-canonical inhibition has already been observed for 
UBE2D2, UBE2D3, and UBE2N, these in vitro experiments were performed with diferent E3 
ligases and some were done with GST-tagged OTUB1, making it impossible to directly compare 
results. To make systematic comparisons and conclusions about the non-canonical activity of 
OTUB1, I looked at inhibition of al seven diferent OTUB1-interacting E2s under the same 






3.2.1 OTUB1 does not disrupt E1 charging of E2 enzymes 
 
Structural studies have shown that OTUB1 sequesters E2~Ub complexes from further 
interacting with a coresponding E3 ligase. The OTUB1 binding surface on E2 enzymes 
overlaps with both the E1 and E3 interfaces (Figure 3.1), so I were interested in whether 
OTUB1 could block E1 charging of the E2 in addition to inhibiting E2 from interacting with the 
E3. Nakada et al. found that OTUB1 blocked UBE2N from interacting with its non-catalytic 
UEV1a and with the E3 ligase, RNF168, but did not disrupt the transthiolation reaction that 
occurs between the E1 and UBE2N(Nakada et al., 2010). I asked whether OTUB1 impacted E1 
charging of other OTUB1-interacting E2s, UBE2D2 and UBE2E1. As shown in Figure 3.2, 
OTUB1 did not inhibit E1 charging of UBE2E1 or UBE2D2. For UBE2E1, I see a reduction in 
autoubiquitylation of the E2 in the presence of increasing concentrations of OTUB1 in both the 
presence and absence of the reducing agent, β-mercaptoethanol (BME), which disrupts the 
E2~Ub thioester (Figure 3.2.b-c). I see a substantial amount of high molecular weight species 
in the presence of BME when OTUB1 is present, which corespond to covalently modified, Ub-
UBE2E1. Therefore, OTUB1 does not disrupt E2 charging by the E1 for UBE2D2 and UBE2E1. 
 
3.2.2 OTUB1 inhibits polyubiquitinating and autoubiquitylating activities of UBE2E1 
 
Although UBE2E1 has been shown to stimulate the DUB activity of OTUB1 (Wiener et al., 
2013), OTUB1 inhibition of this E2 has not been studied. UBE2E1 is a Class II E2 that contains 
an N-terminal extension that restricts E2 activity to predominantly monoubiquitinate substrates 
(Banka et al., 2015; Schumacher et al., 2013). The N-terminal extension serves to regulate and 
limit the processivity confered by the Ubc domain, as entirely removing the N-term extension 
results in a significant increase in polyubiquitinating activity (Schumacher et al., 2013). Fusing 
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the N-terminal extension of UBE2E1 to a highly processive E2, UBE2D2, which only contains a 
Ubc domain, severely restricted the chain building activities of UBE2D2 (Schumacher et al., 
2013). In addition, the N-terminal extension of UBE2E1 is intramolecularly autoubiquitinated in 
vitro (Banka et al., 2015), which further atenuates the polyubiquitinating activity of this E2 and 
subsequent transfer of ubiquitin to an E3 ligase (Banka et al., 2015). Mutating al N-terminal 
extension lysine residues to arginines in UBE2E1, UBE2E2, and UBE2E3 resulted in E2 activity 
comparable to that of the Ubc domain alone (Banka et al., 2015). A high-throughput assay 
revealed that, in vivo, the N-terminus of UBE2E1 is ubiquitinated at multiple sites (Kim et al., 
2007) and UBE2E enzymes are imported into the nucleus when ubiquitinated (Plafker et al., 
2004). 
 
I asked whether OTUB1 can inhibit the both polyubiquitinating and autoubiquitylating activities 
of UBE2E1. I performed a time course assay where I could observe inhibition by OTUB1 in the 
absence and presence of an E3 ligase (Figure 3.3). In the absence of an E3, there is a 
persistent high molecular weight band (indicated by the green star between 37 and 25 kDa) that 
is unafected by reducing conditions. When bloting for UBE2E1, the higher molecular weight 
band coresponds to one or two ubiquitin molecules covalently atached to UBE2E1, or the 
autoubiquitylated UBE2E1 (Figure 3.3.b). Addition of the E3 ligase, RNF4, stimulates synthesis 
of polyubiquitin chains by UBE2E1. Immunobloting for either UBE2E1 or K48-linked 
polyubiquitin shows that both the polyubiquitinating and autoubiquitylating activities of UBE2E1 
are stimulated with the presence of RNF4, as shown by the large smears (Figure 3.3.b). In the 
K48 Ub immunoblot, the large smears corespond to multiple diferent ubiquitinated species: 
atachment of multiple polyubiquitin chains to UBE2E1 and/or RNF4, as wel as a population of 
free K48 linked chains formed by UBE2E1 in the presence of RNF4. The addition of saturating 
amounts of catalyticaly inactive OTUB1(C91S) significantly reduces the polyubiquitinating 
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activity of UBE2E1 in the presence and absence of RNF4 (Figure 3.3b). These results show 
that OTUB1 inhibits the ubiquitin conjugating activity of UBE2E1 in a manner that is similar to 
that observed for other OTUB1-interacting E2s such as UBE2D2, UBE2D3, and UBE2N (Chen 
et al., 2016; Nakada et al., 2010). Unlike these E2s, OTUB1 simultaneously disrupts both the 
polyubiquitinating activity as wel as the autoubiquitylating activity of UBE2E1.  
 
The biological significance of OTUB1 inhibition of UBE2E1 was demonstrated by a study from 
the Wolberger lab, which showed that depleting OTUB1 in both mice and human cels 
destabilizes of UBE2E1 (Pasupala et al., 2018). Wild type levels of UBE2E1 could be restored 
in a knockdown by expressing either wild type or catalyticaly inactive OTUB1, but not by an 
OTUB1 T135R mutant that is defective in binding to E2 enzymes (Juang et al., 2012; Pasupala 
et al., 2018). Our in vitro results (Figure 3.3) are consistent with a model in which OTUB1 
stabilizes UBE2E1 by inhibiting autoubquitylation. This model is supported by a cel-based study 
showing that OTUB1 rescues UBE2E1 from being degraded by the proteasome. Taken 
together, these results describe a novel role of regulation for the OTUB1:E2 complex and 
constitute the first instance where OTUB1 directly modulates the stability of an E2 enzyme. 
 
While doing seting up the experiment for OTUB1-facilitated inhibition of UBE2E1 E2 activity, I 
ran an experiment using wild-type (wt) OTUB1 as a control (Figure 3.4). Since UBE2E1 has 
been found to form K48 chains (David et al., 2010), I was expecting to see an overal reduction 
in the ubiquitinated proteins in comparison to the experiment run with the catalytic mutant, 
OTUB1 C91S. The reduction in ubiquitination should have been atributed to numerous events: 
cleavage of K48 chains by OTUB1, and inhibition of both polyubiquitinating and 
autoubiquitylating activities by UBE2E1. However, this was not the case. Wt OTUB1 was less 
capable of inhibiting the polyubiquitinating activity of UBE2E1, as there was a significant fraction 
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of ubiquitinated proteins. I repeated this experiment multiple times and received the same result 
each time.  
 
 
3.2.3 OTUB1 inhibits polyubiquitinating activities of UBE2E2 and UBE2E3 yet only 
inhibits autoubiquitylation of UBE2E2 
 
After doing an in-depth analysis of non-canonical inhibition of UBE2E1 by OTUB1, I asked 
whether OTUB1 inhibits both poly- and auto-ubiquitylation activities for the other E2s within the 
UBE2E family of E2s that are known to interact with OTUB1. UBE2E1, UBE2E2, and UBE2E3 
difer from the other OTUB1-interacting E2s in that they are Class II E2s, which contain an N-
terminal extension to the conserved UBC domain (Stewart et al., 2016 ). UBE2E enzymes have 
previously been shown to predominantly mono-ubiquitinate E3 ligases (Schumacher et al., 
2013) and are intramolecularly autoubiquitinated on an N-terminal extension lysine (Banka et 
al., 2015) (Figure 3.5.a). The efect of OTUB1 on the poly- and auto- ubiquitylating activities of 
UBE2E2 and UBE2E3 has not been explored.  
 
I assayed the ability of OTUB1 to inhibit the autoubiquitylation and free chain K48 synthesis by 
UBE2E2 and UBE2E3 in the presence of the E3 ligase, RNF4. I asked in what concentration 
range is OTUB1 efective at inhibiting E2 activity. Since the previous study (Figure 3.3) of 
UBE2E1 only looked at inhibition at a single concentration of OTUB1 (10 μM), this E2 was also 
included in the assays. I used a gel-based assay to monitor the ubiquitylating activity of each E2 
over time in the presence and absence of the E3 ligase, RNF4, as wel as with increasing 
concentrations of OTUB1. Immunobloting using antibodies against either the E2 or K48 were 
used to track E2 autoubiquitylation and K48 free chain synthesis. In the absence of RNF4, al 
UBE2E proteins are autoubiquitinated (Figure 3.5.b-c). The ubiquitinated E2 is stable in 
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reducing conditions, indicating that it is not the E2~Ub thioester, but rather autoubiquitylated 
UBE2E1, UBE2E2, and UBE2E3 (Figure 3.5.b). Moreover, in the absence of RNF4, al UBE2E 
enzymes form a smal amount of K48 chains (Figure 3.5.c). In the presence of RNF4, 
polyubiquitinating activity for al UBE2E enzymes is significantly increased, which is evident in 
the diUbiquitin bands and higher molecular weight smears when bloting for K48 chains (Figure 
5c). 
At increasing concentrations of OTUB1 (0.1 - 50 μM), I tracked the disappearance in both the 
poly-ubiquitinating activity of K48 free chains and autoubiquitylation of UBE2E enzymes. For 
UBE2E1, there was a drastic reduction in both autoubiquitination and K48 poly-ubiquitination in 
the presence of 1-10 μM OTUB1, a range that spans the value for the Kd (7.3 μM) for binding of 
OTUB1 and UBE2E1 (Figure 2.2). For UBE2E2, both K48 autoubiquitination and poly-
ubiquitination were greatly reduced at concentrations of OTUB1 between 0.1–1 μM. There was 
a significant reduction in band intensity for Ub-UBE2E2, as wel as a reduction in K48 smears. 
Similar to UBE2E1 and UBE2E2, there was a significant decrease in UBE2E3 K48 poly-
ubiquitination with addition of OTUB1 at concentrations between 1–10 μM. Unexpectedly, 
however, it was not possible to fuly inhibit autoubiquitination of UBE2E3, even at concentrations 
of OTUB1 as high as 50 μM. These results suggest that OTUB1 may serve to primarily inhibit 
poly-ubiquitination of UBE2E3, but not autoubiquitylation. It may be possible to prevent 
autoubiquitylation of UBE2E3 with larger concentrations of OTUB1 but those quantities would 
not be in a plausible physiological range found in the cel. I conclude that OTUB1 inhibits 
autoubiquitination of UBE2E1 at concentrations between 1-10 μM and of UBE2E2 at 
concentrations between 0.1-1 μM. In the case of UBE2E3 however, I did not observe inhibition 
of autoubiquitination over physiological concentrations of OTUB1.  
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3.2.4 OTUB1 facilitated inhibition of UBE2D enzymes in the presence of E3 ligase, RNF4 
 
Although OTUB1-facilitated inhibition of UBE2D2 (Nakada et al., 2010) and UBE2D3 (Baieti et 
al., 2016; Sun et al., 2012) has already been observed, I wanted to make direct comparisons for 
al OTUB1-interacting E2s with our gel based assays. Moreover, prior inhibition studies reported 
for UBE2D2 and UBE2D3 were done using a GST-fused OTUB1(C91S) and in the presence of 
the RING-E3 ligase, TRAF6 [20]. For a more consistent comparison, I performed the gel-based 
assays for UBE2D family of proteins using untagged OTUB1(C91S) and the RING-E3 ligase, 
RNF4 (Figure 3.6.a). I then bloted for Ub, since UBE2D proteins form a variety of chain types 
(Figure 3.6.b) (Brzovic and Klevit, 2006; Brzovic et al., 2006; David et al., 2010; Plechanovov et 
al., 2012). In the absence of an E3 ligase, al UBE2D proteins exhibited limited ubiquitin 
conjugating activity, which is consistent with previous findings for most E2s (David et al., 2010; 
Ernst et al., 2013; Ye and Rape, 2009). There was a significant enhancement of activity, as 
evidenced by the large smears signifying multiple polyubiquitin species with the addition of the 
E3. There was a stark reduction in activity with just 1—10 μM of OTUB1. Previous results 
observed persistent light smears when bloting for Ub in reactions containing UBE2D2/UBE2D3 
in the presence of TRAF6 at concentrations 0—4 μM OTUB1 (Nakada et al., 2010). In 
congruence with previous studies, our results show that OTUB1 inhibits the UBE2D family of 
enzymes from polyubiquitinating with RNF4 over a concentration range of 1—10 μM.  
 
I atempted a more quantitative approach to measuring inhibition by determining values for each 
half-maximal inhibitory concentration, IC50 (Figure 3.6.c). I measured the rates for E2 activity by 
quantifying the disappearance of monoubiquitin as the ubiquitin was activated, conjugated, and 
used to form chains over time. Using a gel-based assay, I tracked the changes in the intensity of 
the ubiquitin band with increasing concentrations of OTUB1. The initial rates of E2 activity were 
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normalized and fit to determine the half-concentration by which OTUB1 efectively sequesters 
ubiquitin conjugation. I found that UBE2D1 was inhibited at a OTUB1 concentration of 5.1 μM, 
UBE2D2 was inhibited at 0.2 μM, and UBE2D3 was inhibited at 1.1 μM. However, IC50s proved 
too dificult to quantify non-canonical inhibition. I determined that quantifying the diferent 
intensities for monoubiquitin over time were unreliable, so I decided not to continue measuring 
IC50s but rather report a range of efective inhibitory concentrations for OTUB1. 
 
3.2.5 OTUB1 inhibition of UBE2N 
 
OTUB1 inhibits UBE2N from heterodimerizing with UEV1a in addition to inhibiting the E2 from 
interacting with the E3 ligases, RNF168, TRAF6, and RNF8 (Nakada et al., 2010; Sato et al., 
2012; Wiener et al., 2012). To make direct comparisons for OTUB1-faciliated inhibition of al E2 
partners, I assayed OTUB1 inhibition of free chain synthesis by UBE2N in the presence of the 
E3 ligase, RNF4 (Figure 3.7). The ubiquitin conjugating activity of UBE2N is enhanced in the 
presence of RNF4 and decreases with increasing concentrations of OTUB1. I observed a 
reduction in ubiquitination at 0.1—1 μM of OTUB1, similar to previous results which saw 




OTUB1 non-catalyticaly inhibits the ubiquitin transfer from E2 to E3. OTUB1 regulates MDM2-
mediated p53 ubiquitination (Chen et al., 2016; Sun et al., 2012) and TGFβ signaling (Herhaus 
et al., 2013) by suppressing ubiquitination by UBE2D proteins. OTUB1 also pays a crucial role 
in the DNA double-stranded break response by non-catalyticaly repressing the K63 ubiquitin 
conjugating activity of UBE2N/UEV1a (Nakada et al., 2010; Sato et al., 2012). Previous studies 
 68 
examined OTUB1 facilitated inhibition of the K63 ubiquitin conjugating activity of UBE2N in the 
absence of an E3 (Wiener et al., 2012) and in the presence of the E3 ligases, RNF8, TRAF6, 
and RNF168 (Nakada et al., 2010; Sato et al., 2012). In addition, inhibition has been observed 
for UBE2D2, and UBE2D3 in the presence of RNF8, TRAF6, and RNF168 (Nakada et al., 2010; 
Sato et al., 2012) with increasing concentrations of a GST-fused OTUB1. As a comparison, I 
looked at inhibition of free chain synthesis for these E2s in the presence of untagged OTUB1 
and the E3 ligase, RNF4. I found that OTUB1 inhibits UBE2N at concentrations of 0.1—1 μM 
which is within the range of the EC50, 0.8 μM (from Chapter 2). Similarly, I observed a stark 
reduction in E2 activity for the UBE2D family of proteins in the presence of 1—10 μM of OTUB1. 
The concentration of OTUB1 needed to inhibit also matches the efective concentration of E2 to 
enhance the DUB activity, 3.9 μM for UBE2D1, 3.8 μM for UBE2D2, and 1.5 μM UBE2D3. I 
therefore conclude that there is a tradeof between the two opposing actions of deubiquitinating 
and ubiquitinating that may be controled by intracelular concentrations ratios of E2 to E2~Ub. 
 
It was recently shown that OTUB1 not only suppresses the K48 ubiquitin conjugating activity of 
UBE2E1 but also inhibits autoubiquitination of the E2 (Pasupala et al., 2018). I asked if this was 
true for the remaining E2s in the UBE2E family, UBE2E2 and UBE2E3. I found that OTUB1 
suppresses the K48 free chain synthesis activity for both of these E2s at concentrations of 1—
10 μM of the DUB. Once again, this range of concentration of OTUB1 fals within the EC50s that 
I determined earlier, 4.6 μM for UBE2E1, 10.9 μM for UBE2E2, and 10.7 μM for UBE2E3. 
Unexpectedly though, OTUB1 inhibits autoubiquitination of UBE2E1 and UBE2E2 but not 
UBE2E3, even at concentrations of 50 μM of the DUB. The Ubc domain sequence of UBE2E 
proteins is conserved with 92% identity to other E2s. However unlike the other E2 partners to 
which OTUB1 binds, UBE2E enzymes possess an N-terminal extension that varies in length for 
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each protein. It is possible that this additional extension accounts for the varied inhibitory 
responses with increasing concentrations of OTUB1. 
 
An interesting result from studying the non-canonical E2 inhibition by OTUB1 was that OTUB1 
C91S was beter at inhibiting UBE2E1 than the wild-type DUB. I checked to make sure that I did 
not switch the proteins and repeated this experiment several times but received the same 
results. It is unclear whether wt OTUB1 is less adept at inhibiting the polyubiquitinating or 
autoubiquitylating activities of UBE2E1. Further analysis is needed to uncover the mechanisms 
that make OTUB1 C91S a beter inhibitor than the native protein. 
 
3.4 Materials and Methods 
 
3.4.1 Protein Expression and Purification 
 
Al E2 proteins, OTUB1 enzymes, and ubiquitin proteins were purified as described previously in 
Chapter 2. Additionaly, E1 (Berndsen and Wolberger, 2011) and E3 (DiBelo et al., 2016) 
(Table 3.1) enzymes were purified as described. 
 
3.4.2 E1 charging assays 
 
E1 charging of select E2 enzymes were caried out through gel based assays. Reactions 
contained 0.15 μM of Uba1 (E1), 2 μM of E2, 12.5 μM of Ub wt in a bufer of 50 mM HEPES pH 
7.5, 300 mM NaCl, 10mM MgCl2, 0.5 mM DTT, and 0.005 % Tween20. To study whether 
inhibition of charging occured with the presence of OTUB1, OTUB1 (C91S) was added at 
concentrations 1, 5, and 10 μM. Reactions were initiated with the addition of 0.15 μM E1 and 5 
mM ATP pH 7.6 and placed in a 37 °C for 10 mins. Assays were quenched with sample bufer 
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that had 400 mM BME (+BME) added to it or had water added to it (-BME). Samples were 
immediately analyzed using SDS-PAGE and stained with Coomasie Briliant Blue. 
 
3.4.3 IC50 Determination 
 
Quantitative IC50s, efective concentration of OTUB1 to inhibit ubiquitin conjugating activity of 
the E2, were determined through gel-based assays. Reactions contained 50 mM HEPES pH 
7.5, 300 mM NaCl, 10mM MgCl2, 0.5 mM DTT, and 0.005 % Tween20. In addition, each 
reaction contained 10 μM 4xSUMO2 substrate, 0.1 μM E1, 2 μM E2, 2 μM RNF4, and 50 μM 
Ub wt with and without specified concentrations of OTUB1 (C91S), log base -8 to -4) at a 
constant temperature of 37 °C. Reactions (10 μL) were initiated with 5 mM ATP pH 7.5 and 0.1 
μM E1 then at specific time points, quenched with SDS-PAGE loading dye containing BME. 
Samples were analyzed by gel electrophoresis on 4–12% gradient polyacrylamide Bis-Tris 
Criterion XT gels (Bio-Rad). For quantitative analysis for IC50 determination, gels were then 
stained overnight with ‘longer staining protocol” for SYPRO Ruby Protein Gel Stain (Thermo 
Fisher Scientific). After staining overnight, gels were further destained in 10% methanol and 5% 
glacial acetic acid for 30 mins before the gel was imaged on the Typhoon Imager (GE 
LifeSciences). The concentration of the ubiquitin consumption band for each time point was 
quantified by densitometry with ImageJ software (Eliceiri et al., 2012). The data was analyzed 
using GraphPad Prism and fit to determine the 50% inhibition concentrations for each E2. 
Experiments were done in triplicate. 
 
3.4.4 Qualitative inhibition gel based assays 
 
Gel-based assays inhibition of E2 ubiquitin-conjugating activity were determined at 37 °C in 
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reaction bufer containing 50 mM HEPES pH 7.5, 300 mM NaCl, 10mM MgCl2, 0.5 mM DTT, 
and 0.005 % Tween20. In addition, each reaction contained 10 μM 4xSUMO2 substrate, 0.1 μM 
E1, 2 μM E2, 2 μM RNF4Δ22, and 50 μM Ub wt with and without specified concentrations of 
OTUB1 (C91S). Reactions (10 μL) were initiated with 5 mM ATP pH 7.5 and 0.1 μM E1 then at 
specific time points, quenched with SDS-PAGE loading dye containing BME. Samples were 
analyzed by gel electrophoresis on 4–12% gradient polyacrylamide Bis-Tris Criterion XT gels 
(Bio-Rad) and were either stained with Coomassie Briliant Blue (Bio-Rad) or transfered to a 
PVDF membrane for a Western Blot. For blots, 4 μL samples run by gel electrophoresis on 4–
12 % polyacrylamide Bis-Tris Criterion XT gels (Bio-Rad) and immediately transfered to a 
PVDF membrane via the Bio-Rad Turbo Transfer system. Al blots were systematicaly blocked 
with 5% BioRad bloting grade blocker in TBST for 1hr at room temperature. Afterwards, they 
were washed thrice with TBST, rocking at room temperature for 10mins. Blots were then 
incubated with primary antibody (Table 3.2), diluted in 2% BSA, 0.02% sodium azide in PBS 
bufer, overnight at 4 °C. The folowing day, blots were washed again three times with TBST for 
10 min intervals before adding secondary antibody, diluted in 5% BioRad bloting grade blocker, 
and let it shake at room temperature for 1 hr. After another round of washes with TBST, 1:1 



















Uba1 100825 117800 5.6 1058 pProEx NA 
RNF4Δ22 5960 18749 5.2 168 pETSUMO SENP2 
Extinction coeficients, molecular weight, and pI were calculated using Expasy. 
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Figure 3. 3 Time course assay for the inhibition of UBE2E1 autoubiquitylation by OTUB1.  
In vitro assay of recombinant proteins showing autoubiquitination of UBE2E1 in the presence and 
absence of the E3 ligase, RNF4, and OTUB1-C91S. (a) Coomassie stained gel of ubiquitination reactions 
containing 0.1 μM UBA1, 5 μM UBE2E1, 1 μM RNF4, 50 μM Ub wt, and 10 μM OTUB1 C91S. The green 
star indicates the persistent higher molecular weight band that was present in reducing conditions. 
Western blot of reactions shown in top panel using antibodies against (b) UBE2E1 (top) and K48-
polyubiquitin (botom). 
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Structural insights into how OTUB1 interacts with a Class II Ubiquitin Conjugating Enzyme, E2 
remain elusive. My results in Figure 3.4 demonstrate that OTUB1 C91S is beter at inhibiting 
the polyubiquitinating activity of UBE2E1. It is unclear why a mutation to the active site of 
OTUB1 would afect its non-catalytic role in inhibiting UBE2E1, especialy since the catalytic 
cysteine, C91, is 15 Å from the closest E2 contacting residue on OTUB1. Preliminary data 
suggest that OTUB1 C91S may actualy bind tighter to UBE2E1 than the wild-type DUB. I 
considered this a fantastic opportunity to obtain a structure of this complex. Although truncated 
or hybrid versions of OTUB1 (Edelmann et al., 2008; Sato et al., 2012; Wiener et al., 2013; 
Wiener et al., 2012) and UBE2E1 (Sheng et al., 2012) have been determined, a structure of ful 
length OTUB1 and UBE2E1 is unavailable. 
I sought to understand the structural mechanisms behind OTUB1 C91S inhibiting the formation 
of poly-ubiquitinated species beter than OTUB1 wt. Extensive binding studies wil be conducted 
to determine whether the reduced inhibition I observed for wt vs the catalytic mutant is 
corelated to the diferences in afinity between the DUB and the E2. This chapter summarizes 
the characterization of interactions between ful-lengths OTUB1 and UBE2E1 as wel as the 








OTUB1 (C91S) binds with similar afinity (~ 7 μM) to UBE2D1, UBE2D3 and UBE2E1 (Figure 
4.1). When testing whether the Kd was also relatively the same for OTUB1 wt (1.5 mM) and 
these E2s (150 μM), I performed the ITC experiments under the same conditions. I found that 
the interactions between OTUB1 wt and either UBE2D1 or UBE2D3 were relatively similar and 
comparable to the measurements of those same E2s with OTUB1 (C91S). However, the binding 
afinity for UBE2E1 with OTUB1 wt was 4 times higher than that of UBE2E1 and OTUB1 
(C91S); OTUB1 (C91S) binds to UBE2E1 with a Kd of 7 μM whereas with OTUB1 wt was 26 
μM. It is very surprising that a single point mutation in the OTUB1 active site should produce 
such a large change in afinity for any E2 partner, as the active site is not near the OTUB1-E2 
interface in structures of either UBE2N (REF: Wiener, 2012) or UBCH5B (REFS: Wiener, 2013; 
Juang 2012) bound to OTUB1. Structural information is needed to address the reason for the 
observed increase in afinity of OTUB1 (C91S) for UBE2E1.  
 
 
4.2.2 Summary of Crystalization Trials 
 
 
 Crystalization conditions were screened for the folowing complexes: (1) UBE2E1: C. elegans 
OTUB1, (2) UBE2E1:wt human OTUB1, (3) UBE2E1:human OTUB1(C91S). Complexes were 
formed by adding equimolar amounts of both proteins to a final concentration of 5-20 mg/mL 
(Table 4.1). In addition, the complex was diluted in 1x bufer containing, 100 mM NaCl and 
0.5mM TCEP-HCl, then screened using JCSG+ (Hampton Research) and HR1422 (Qiagen), 
Mosquito 96-wel plates at a 1:1 ratio (0.5 μL). Needles formed in 100 mM HEPES pH 7.0 and 
10% PEG 6000 (Figure 4.2). Three-dimensional crystals formed with 100 mM CHES pH 9.5 
and 20% PEG 8000. Larger screens (24-wel plates) were thus made to reproduce the initial hit 
but to no avail. Thus, an additive screen (Hampton Research) was used in addition to the 
CHES/PEG bufer to optimize crystal conditions. It is important to note that crystals grew at 
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protein concentrations of 7.5, 10, and 20 mg/mL. However, only crystals grown from 7.5 mg/mL 
protein solution were suficiently large and wel-separated to be handled. This condition was 
therefore utilized for al further crystal tests. 
 
Using the conditions for the initial hit, an additive screen was performed to optimize 
crystalization conditions. The additive screen produced several hits that ranged from crystal 
showers to large single crystals (Figure 4.3). Two promising conditions that were taken to the 
next stage of optimization were those grown in 10 mM strontium chloride and in 100 mM 
Spermidine (Figure 4.4). Crystals with the coresponding additive were grown by mixing 1 μL of 
complex and 1 μL of wel solution in a 1:1 ratio. The resulting crystals ranged in size from 0.1-
0.3 μm in length and were always pyramid shaped.  
 
 
4.2.3 OTUB1 (C91S):UBE2E1 crystals contain both proteins yet yield low resolution data 
 
 
Before determining the resolution to which these crystals difracted x-rays, I first sought to 
determine whether both proteins were present. Two sets of crystals grown 1:1 in 1 μL hanging 
drops were selected to evaluate protein composition. Crystals were retrieved using a 0.1-0.2 μm 
loop and washed twice with 2 μL of mother liquor (Figure 4.5). After washing the crystal in fresh 
bufer five times in the mother liquor, the crystal was placed into 2 μL of bufer and vortexed in 
order to crush it. Samples of each wash and the final homogenized crystal were run on an SDS-
PAGE gel and stained with Sypro-Ruby (Thermo Fisher Scientific). From the final sample 
containing just the crystal I determined that both proteins were indeed present at a 1:1 ratio 
which was highly encouraging. This procedure was repeated again with a different crystal grown 
in a diferent condition (Figure 4.5, crystal 2), which also contained both proteins. 
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To prepare the crystals for x-ray difraction data colection, I experimented with 
cryopreservation conditions. First, I atempted to loop crystals with and without the 
cryoprotectant, 20% PEG 500, and found that one in every fifteen crystals that I shot actualy 
yielded a difraction patern extending to around 10 Å resolution, for crystals grown in 20 °C 
(Figure 4.6.b-f). From these results, I determined that the protein crystals were most likely 
mosaic, thus producing a low resolution. The next step was to try serial dehydration in an 
atempt to lower the mosaicity (Figure 4.6.c-d). Serial dehydration was atempted using two 
diferent dehydrators and yet difraction only improved to ~ 9 Å. Serial dehydration was 
performed by fishing out single crystals and placing them into solutions of PEG 8000 that was 
diluted in wel solution. Dehydration started from 18% and increasing increments by 2% until a 
final solution of 28% PEG 8000 coated the crystal. However, this did not improve the difraction. 
Another atempt at reducing mosaicity was growing crystals at 4 °C to see if I could slow down 
crystal formation and thereby improve the resolution (Figure 4.6.e). However, this failed to 
improve the resolution. In fact, litle to no difraction was observed for al the atempts at 
optimization. Although crystal growth was highly encouraging, I were unable to achieve a high 
resolution using the three diferent methods: cryoprotectant, serial dehydration and changing 
growth conditions. 
 
4.3 Future Directions 
 
 
The molecular basis for the higher afinity of OTUB1 (C91S) for UBE2E1 as compared with wt 
OTUB1 remains unknown. Should it ultimately be possible to obtain wel-difracting crystals, 
structural studies of this complex wil elucidate why the C91S OTUB1 mutant binds more tightly 
to UBE2E1 than wt. Various structures of both OTUB1 (C91S) (Edelmann et al., 2008; Sato et 
al., 2012; Wiener et al., 2012) and UBE2E1 (Sheng et al., 2012) have been solved previously, 
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although not in complex with one another and not as their ful length moieties. In addition, since 
this would be the first structure using ful length constructs of both proteins, it wil be interesting 
to see if there is any structure in the predicted unfolded N-terminal tails that has not been 
observed previously.  
 
Crystals grown with the additive, 100 mM spermidine, produced consistently large crystals that 
contained both protein in equal ratios. Several methods, such as changing cryoprotectant, serial 
dehydration and changing growth conditions, were employed to improve the resolution to which 
the crystals difractive. Despite these eforts, resolution remained low, at 8-9 Å. It is possible that 
alternative approaches could lead to wel-difracting crystals. Limited proteolysis can be used to 
identify regions, like the unfolded N-terminal regions, that can be removed without 
compromising crystal contacts. Additionaly, the mutant OTUB1 (C91A) can also be used to 
screen; since cysteine to serine mutations yields a reduction in charge and spatial orientation, 




4.4.1 Protein expression and purification 
 
 Ful length UBE2E1 and OTUB1 (C91S) were expressed and purified as described in the 
Chapter 3.2 Methods Section. Expression and purification of UBE2D1, UBE2D3, and OTUB1 wt 








4.4.2 ITC experiments 
 
Al experiments were conducted in bufer conditions of 25 mM HEPES pH 7.5, 150 mM NaCl, 
0.5 mM TCEP-HCl at 25°C. Proteins of interest were dialyzed together overnight twice in 4 L at 
4 °C. Dialysis occured over two nights to ensure that both proteins were in equilibrium within 
the bufer. E2s (150 μM) were placed in the cel while 1.5 mM OTUB1 or OTUB1 (C91S) was 
titrated in. UBE2D1 and UBE2D3 were also measured as controls. Al ITC experiments were 
performed on a MicroCal iTC200 system (Malvern). A total of 20 injections of 40 μl titrant were 




Table 4. 1 Example table used to determine concentrations and volumes to use for 
crystal trays. 
 
Protein 7.5 mg/mL      
Total Volume 30 μL      
[UBE2E1] 21400 g/mol 0.000141 M    
[OTUB1 (C91S)] 31850.9 g/mol 0.000141 M    
total g/mol 53250.9 g/mol      
        
 A dilution E [], M MW, g/mol Volume 
UBE2E1 2.9 10 25690 0.001129 21400 3.74 μL 
OTUB1 (C91S) 1.6 10 23840 0.000671 31850.68 6.3 μL 
     
1x 
bufer 19.9 μL 




Figure 4. 1 Binding of E2s to OTUB1 (C91S) vs. (wt).  
OTUB1 (1.5 mM) titrated into 150 μM E2 within the cel. Proteins were dialyzed in 50 mM HEPES pH7.5, 
150 mM NaCl, and 0.5 mM TCEP-HCl bufer twice overnight. Kd values associated with each interaction 














Kd: 9.3 ± 1.7 μM
Kd: 8.1 ± 3.6 μM




Kd: 14.3 ± 1.3 μM
Kd: 8.1 ± 2.1 μM








Figure 4. 2 Crystals hits for UBE2E1:OTUB1 (C91S). 
(a) Schematic of seting the 96-wel plate with 600 nL hanging drops of JCSG+ condition b) 100 mM 





600 nL hanging drops
7.5 mg/mL OTUB1:UBCH6
Incubate at RT for 30 mins
Then on ice for ~3 hrs
Make wel soln
100 μL JCSG+
Lay Tray via mosquito








Figure 4. 3 Additive Screen  
(a) Methodology for making 600 nL (300 nL protein with 300 nL bufer) hanging drops using the Mosquito 
(b) Crystal hits with their additives. 
15 % 6-Aminohexanoic acid10 mM Strontium chloride
100 mM Spermidine 500 mM Glycine
a Additive Screen
96 wel plate
600 nL hanging drops
7.5 mg/mL OTUB1:UBCH6
Incubate at RT for 30 mins
Then on ice for ~3 hrs
Make wel soln
90 uL of bufer:




Lay Tray via mosquito









Figure 4. 4 Larger scale optimization crystal trials. 
(a) Schematic of methology for laying the 24 wel trays, 1:1, 2 μL drops, 500 μL wel solution (450 μL 
bufer with 50 μL of 100 mM Spermidine. (b) Crystals grown with 10 mM Strontium chloride. c) Example 
crystals grown with 100 mM Spermidine. 
100 mM CHES pH 9.1
14 % PEG 8000
10 mM Strontium chloride
100 mM CHES pH 9.1
16 % PEG 8000
100 mM Spermidine
a 24 wel plate
2 μL hanging drops, 1:1
7.5 mg/mL OTUB1:UBCH6
Incubate at RT for 30 mins
Then on ice for ~3 hrs
Make wel soln
450 μL of bufer:
100 mM CHES pH 9.3
20 % PEG 8000
with
50 μL of additive
Lay Tray by hand




100 mM CHES pH 9.3









Figure 4. 5 Both UBE2E1 and OTUB1 (C91S) are present in single crystals.  
The skin for each drop was removed and a single crystal was subsequently washed multiple times. Al 
wash solutions were run on an SDS-PAGE gel. Gel was stained using Sypro-Ruby stain overnight at 
room temperature. 
a
Crystal 1 wel solution: CHES pH 9.0, 16 % PEG 8000, and 10 mM Spermidine
Crystal 2 wel solution: CHES pH 9.1, 16 % PEG 8000, and 10 mM Spermidine
skin: cut and removed the skin of percipitate covering the drop and resuspended 
  with 5 μL of wel solution 
1: loop single crystal and wash with fresh 5 μL of wel solution 
2: wash again with fresh 5 μL of wel solution 
3-5: repeat step 2
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Chapter 5 Conclusion and Future Directions 
 




Deubiquitinating enzymes are modular, frequently found in complex with another protein, which 
can drive specificity and enhance functionality (Ritorto et al., 2014; Turcu et al., 2009). Several 
DUBs associate with E3 ligases and to a lesser extent, E2 enzymes, suggesting that DUBs 
regulate ubiquitylation in addition to the canonical deubiquitylating roles. In the apo form, 
OTUB1 exhibits low isopeptidase activity which I confirmed in this study (Wang et al., 2009; 
Wiener et al., 2013). I determined through ITC that the binding afinity of this DUB for K48 
diubiquitin was also low, therefore reduced cleaving activity is atributed to low afinity. OTUB1 
is a unique DUB that associates with seven E2s in vivo. These interaction partners cross-
regulate one another. Additionaly, by interacting with these E2s enhances the DUB activity of 
OTUB1 over a broad range of stimulation. The biological implications for this cross-regulation 
remained understudied. In this thesis I showed that the cross-regulatory complex, OTUB1:E2 
partners, are capable of forming and are functional in vivo. 
 
Based on known celular concentrations in the cel, I predicted that OTUB1 binds to the E2 first 
before interacting with K48 diUbiquitin. The total ubiquitin concentration in mammalian cels is 
estimated to be between 20-85 μM depending on the cel type (Clague et al., 2015; Kaiser et al., 
2011). These numbers accounts for al forms of ubiquitin: free, mono-, conjugated to enzymes, 
and in chains. Given that I measured the binding afinity of OTUB1 for K48 diUbiquitin to be 84 
μM, it is unlikely that OTUB1 wil encounter these high levels of substrate in celulo. In support 
of OTUB1:E2 complex (Figure 2. 11, A) forming before OTUB1:K48 diUbiquitin (Figure 2. 11, 
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B), the combined concentrations of UBE2D3 and UBE2N is about 3.7 μM (Kulak et al., 2014; 
Schwanhäusser et al., 2011) which I determined to be similar to the binding afinities between 
OTUB1 and the diferent E2 partners. As a result of forming OTUB1:E2, the E2 increases the 
afinity of OTUB1 for K48 diUbiquitin producing an enzyme that is more active at ubiquitin 
concentrations that it wil more likely come across in celulo.  
 
I then determined the efective E2 concentrations needed to produce a stimulated response in 
deubiquitinating activity, and found that the EC50s for UBE2N and UBE2D3 matched the 
intracelular concentrations determined through mass spectrometry and proteomic studies in the 
cel (Schwanhäusser et al., 2011). Therefore enhancement produced in the presence of these 
E2s is plausible under normal physiological conditions in the cel. In fact, UBE2N and UBE2D3 
rank as some of the most abundant E2s to be found in both HeLa and Swiss 3T3 cels (Kulak et 
al., 2014; Schwanhäusser et al., 2011; Stewart et al., 2016). From our kinetic results I learned 
that UBE2D3 robustly stimulated OTUB1’s DUB activity by lowering the afinity of the enzyme 
for K48 diUbiquitin. In addition, UBE2D3 possessed the largest Hil Slope when fiting the 
activity curves for determining EC50s which signifies that binding of the E2 induces a favorable 
conformational change in OTUB1 that preferentialy drives binding of K48 diUbiquitin to both 
ubiquitin binding sites.  
 
I was puzzled by the data I determined for UBE2N. Of al the E2s that I measured UBE2N had 
lowest EC50 which signifies that smal amounts of UBE2N are needed to stimulate OTUB1. 
UBE2N also had the lowest Hil Slope (0.7) which could indicate that binding of this E2 to 
OTUB1 induces a conformational change to the DUB that is less productive at binding to K48 
diUbiquitin. This negative cooperativity could help to explain why I found that UBE2N only mildly 
stimulates the DUB activity of OTUB1. In its apo form, OTUB1 possesses an unfolded N-
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terminus that spans 45 residues (Edelmann et al., 2008; Wang et al., 2009; Wiener et al., 2012). 
Based on structural analysis, when OTUB1 solely binds to UBE2N partial folding of the N-
terminus (residues 39-45) occurs along with conformational changes in the globular fold of 
OTUB1 (Wiener et al., 2012). Based on structural analysis, when OTUB1 solely binds to UBE2N 
partial folding of the N-terminus (residues 39-45) occurs along with conformational changes in 
the globular fold of OTUB1 (Wiener et al., 2012). I hypothesize that premature folding of the N-
terminal helix can lead to unproductive and unfavorable interactions within the proximal ubiquitin 
binding site.  
 
OTUB1 non-catalyticaly inhibits the ubiquitin transfer from E2 to E3. OTUB1 regulates MDM2-
mediated p53 ubiquitination (Chen et al., 2016; Sun et al., 2012) and TGFβ signaling (Herhaus 
et al., 2013) by suppressing ubiquitination by UBE2D proteins. I observed a stark reduction in 
E2 activity for the UBE2D family of proteins from 1—10 μM of OTUB1. I also found that OTUB1 
inhibits UBE2N at concentrations of 0.1—1 μM which is within the range of the EC50, 0.8 μM. 
The concentration of OTUB1 needed to inhibit UBE2D1, UBE2D2, UBE2D3, and UBE2N 
matches the intracelular concentration of the DUB which has reported to be ~0.5 μM in HeLa 
and Swiss3T3 cels (Kulak et al., 2014; Schwanhäusser et al., 2011) and 1.1 μM in mouse 
embryonic fibroblasts (MEFs) (Schwanhäusser et al., 2011). I therefore conclude OTUB1 is 
capable of inhibiting these E2 enzymes under biological conditions in the cel.  
 
Our studies show that OTUB1 is capable of inhibiting the polyubiquitinating activity of al E2 
partners over physiological concentrations of the DUB and I also show that E2s, UBE2D3 and 
UBE2N, are capable of stimulating isopeptidase activity of OTUB1 over biological 
concentrations. I prove through biochemical methods that there is a tradeof between the two 
opposing actions of deubiquitinating and ubiquitinating that may be swayed by the ratio of 
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charged to uncharged E2s as wel as the local concentration of free ubiquitin. The DUB activity 
of OTUB1 is enhanced in the presence of both charged and uncharged UBE2D2 however 
cleavage is significantly reduced for UBE2D2~Ub in increasing concentrations of free Ub. 
(Wiener et al., 2013). OTUB1:E2. E2 charging states in vivo depend greatly on the type of cel 
lines used. In HeLa cels UBE2N exists only in a charged form but as a mixture of un/charged 
states in U2OS cels, the UBE2D family of enzymes on the other hand were primarily uncharged 
in both cel lines (Wiener et al., 2013). Given that a minimal concentration of 0.1-1 μM OTUB1 
was able to significantly reduce the polyubiquitinating activity of UBE2N, OTUB1 primarily 
inhibits UBE2N in HeLa cels whereas in U2OS cels, OTUB1 can both be inhibited and 
stimulated by UBE2N. I strongly believe though that OTUB1 serves to primarily inhibit this E2 
given how weakly (KM = 24.1 μM) the DUB activity is stimulated in the presence of UBE2N. I 
atribute this lower stimulation to negative cooperativity (Hil slope < 1) that occurs when UBE2N 
interacts with OTUB1. Additionaly, high concentrations of free ubiquitin has been shown to 
drive the balance towards the inhibitory OTUB1:E2 complex (Wiener et al., 2013). In HeLa and 
U2OS cels where the charged ratio of UBE2D enzymes is similar, regulation of the cross-
regulatory complex may also be determined by local celular concentration of free ubiquitin. 
 
 
5.2 Future Directions 
 
Based on the work covered in this thesis, I was able to make conclusions about which cross-
regulatory OTUB1:E2 complexes function in vivo. However, one of the main questions that I 
was unable to answer was why these particular seven E2s? The Ubc domain of these E2s 
share sequence similarity of 90%. By taking the known structures of each seven E2 and aligning 
the structure to UBE2D2 in PDB:4LDT, al E2s contact OTUB1 (within 3 Å) using similar 
residues. When aligning the structure of CDC34, an E2 that should not interact with OTUB1, 
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similar residues to the seven OTUB1-interacting E2s are also capable of contacting the DUB. 
The distinguishing factor that alows the seven E2s to interact with OTUB1 is stil unknown 
based on structural analysis. Another interesting detail is that from studying al the structures of 
OTUB1, binding of the E2 changes very litle to the actual E2 binding site. Conformational 
changes in the globular fold, distal and proximal ubiquitin binding sites, account for the largest 
diferences in structure (Edelmann et al., 2008; Sakata et al., 2010; Wiener et al., 2013; Wiener 
et al., 2012). More research is needed to help distinguish why OTUB1 interacts with the select 
seven E2s in vivo over any other ubiquitin conjugating enzyme.  
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This appendix summarizes my crystalography side project that I worked on in addition to my 
thesis. In this section I discuss my atempts to obtain a structure of wild-type tetraubiquitin 
(tetraUb) associated with a cyclic peptide, Ub4_a (Figure A.1.a). The process of ubiquitination 
and deubiquitination are involved in several diferent biological systems including oncogenic and 
tumor-suppressor pathways. As a result, the ubiquitin system is an excelent drug target for 
cancer therapy. Some drugs target DUBs, reacting with the active site cysteine and inhibiting al 
isopeptidase activity (Farshi et al., 2015; Goldberg, 2012; Harigan et al., 2018). Another 
approach for drug development is targeting the ubiquitin molecule itself. A chemical genetic 
screen found that smal molecules ‘ubistatins’ target ubiquitin by binding to both mono- and 
poly-ubiquitin chains (Verma et al., 2004). However promising, ubistatins bind with low afinity to 
their ubiquitin targets and have low chains specificity (Nakasone and al., 2017). The Brik lab at 
the Technion Institute in colaboration with the Suga lab at the University of Tokyo, synthesized 
cyclic peptides that bind to various forms of ubiquitin, including chains (unpublished data). 
These cyclic peptides provide a promising approach towards drug discovery because they are 
smal enough to emulate drug-like characteristics (Nakasone and al., 2017) in addition to 
binding tightly to their interacting ubiquitin partners. A particular cyclic peptide, Ub4_a, bound 
with extremely high afinity to K48 tetraUb (Figure A.1.d). K48-linked polyubiquitin chains signal 
for proteasomal degradation of a protein substrate. And by binding tightly to K48-linked chains it 
could inhibit recognition by the proteasome and subsequent substrate degradation (Goldberg, 
2012; Verma et al., 2004). It is very rare to see such tight afinity for the ubiquitin system, so I 
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asked how the cyclic peptide was interacting with tetraUb to produce such a low Kd. I sought to 
understand the molecular interactions between this complex through X-ray crystalography. 
 
A.2 Materials and Methods 
  
A.2.1 Purification of Ub4 
 
TetraUb was made enzymaticaly by adding 0.1 μM Uba1, 20 μM UBE2K, 500 μM Ub wt, 5 mM 
ATP pH 7.5, 1 mM MgCl2, 1 mM DTT, and 50 mM Tris pH 7.5 in a total reaction volume of 1000 
μL. Reactions incubated for 18 hrs at 37 °C and were diluted with 10x the reaction volume with 
Ubiquitin Bufer A (50 mM Ammonium acetate, pH 4.5, 10 mM NaCl, 1 mM DTT). Diluted 
samples were then spun down and filtered to remove any proteins that crashed out in the 
process. Filtered protein solution was then purified using a SOURCE 15S 20 mL column. 
Proteins eluted with increasing concentrations of Ubiquitin Bufer B (50 mM Ammonium acetate, 
pH 4.5, 1 M NaCl, 1 mM DTT). Diferent ubiquitin species corelated with a particular peak (i.e.: 
first peak always coresponds to monoUb, second is diUb, and so forth). Samples were run on a 
SDS-PAGE gel and stained with Coomasie to ensure that the fraction was indeed clean. 
Fractions coresponding to tetraUb were pooled together, dialyzed into 50 mM Tris pH 7.6, 150 
mM NaCl, and 2 mM DTT, then concentrated to 14 mg/mL. 
 
A.2.2 Dissolving Ub4_a 
 
The Brik lab sent us roughly 1 mg of lyophilized Ub4_a. I weighed out ~0.5 mg of this sample 
and resuspended it to 10 mg/mL with 20 μL of DMSO, this stock was then kept at 4 °C. I kept 
the rest of the lyophilized sample at -20 °C. I then used the nanodrop to determine the 
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concentration of Ub4_a in DMSO which was used to calculate the amount needed to form the 
complex. 
 
A.2.3 Crystal Screen and freezing of Ub4:Ub4_a 
 
To make the Ub4:Ub4_a complex, I made 7 mg/mL of complex since the previous structure of 
K48 tetraUb solved in the lab grew in 8 mg/mL which was concentrated in 50 mM Tris pH 7.6, 
10 mM NaCl, 1 mM EDTA, and 1 mM DTT (Eddins et al., 2006). Conditions for seting up the 
complex are described in Table A.1. The crystal growth conditions for these previous crystals 
were: 100 mM MES pH 6.5, 2 M Ammonium sulfate, 14% (w/v) PEG 400. Unfortunately, 
because Ub4_a is so smal I could not simply run these crystals on a gel to determine whether 
both proteins were present in my crystals. Therefore, I needed to shoot each one and solve the 
structure to see if they contained both tetraUb and the cyclic peptide. 
 
Using the 7 mg/mL complexes, I set up 4 diferent 96-wel crystal screens: JCSG+ (Molecular 
Dimensions), Protein Complex Suite (Qiagen), Wizard Screen (Molecular Dimensions), and 
Index Screen HT (Hampton Research) (Figure A.2). The largest crystals were recapitulated in a 
larger 24-wel screen with conditions that were dependent on the initial hit (Figure A.3). Crystals 
were cryoprotected by soaking in wel solution with 35% glycerol, 30% PEG 400, or 2 M 
ammonium sulfate. Crystals were looped and washed in a cryoprotectant for less than one 





A.2.4 Data Colection and Processing 
 
 
Some of the largest crystals were shot at the Brookhaven National Laboratory (NSLS I) where I 
got 1.7 – 3Å resolution data. Data was processed and indexed using the XDSGUI. The best 
data belonged to crystals grown in 100 mM BisTris pH 5.5, 200 mM ammonium sulfate, 25% 
and PEG 3350. Structures were solved using molecular replacement with MOLREP from the 
CCP4 suite using the coordinates of either a single or two copies of human tetraubiquitin (PDB 
ID 2VO6) as a search model. Refinement via Molecular Replacement using Phenix 7.0 and 
visualized using COOT for model-building. Three additional rounds of refinement were 
performed. Maps and models the BisTris crystals are depicted in Figure A.3. Based on these 
data, it does not appear that I colected at least five other datasets from NSLS I that are < 3 Å. 
A majority of the data was unable to be processed in XDSGUI because the difraction data 
showed multiple loons, indicating multiple crystals present in the loop. 
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Section A Crystalization of tetraubiquitin in complex with a cyclic peptide 
 
Table A. 1 Reaction setup for Complex of Ub4:Ub4_a 
Protein 7 mg/mL   
Total Volume 100 μL   
 Molecular weight Concentration of both Proteins 
[Ub4_a] 1766.5 g/mol 0.00020823 mol/L 
[Ub4] 31850.68 g/mol 0.00020823 mol/L 
total g/mol 33617.18 g/mol   
 





[Ub4_a] in DMSO 5 10 8605 0.00581058 1766.5 3.58  
[Ub4] 1.6 10 5960 0.00268456 31850.68 7.76  
      88.66 1x Bufer 
 
This table depicts the type of concentrations needed in order to set up the complex for crystal screens. In 
this example, 100 μL was the final volume and both proteins needed to be at 208 μM in order to make a 7 
mg/mL complex. 1x Bufer needed to dilute the concentrated proteins was 50 mM Tris pH 7.6, 150 mM 
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